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ABSTRACT
Heart rate variability (HRV) and barorefl ex sensitivity (BRS) can be used to examine 
non-invasively autonomic cardiovascular regulation. Although impairments in HRV 
and BRS are related to adverse outcomes in various populations, the factors that 
determine these autonomic markers are poorly understood.
The present study applied time and frequency domain analyses of the R-R interval and 
arterial pressure variability (APV), and cross-spectral analysis of BRS, to examine 
the associations of these autonomic measures with life style, psychological factors, 
physical fi tness, pulse pressure, hypertension, and other cardiovascular risk factors. 
The beat-to-beat variability of pulse pressure and its associations with cardiovascular 
risk factors were also studied.
The results show that HRV is reduced in untreated middle-aged hypertensive subjects. 
Higher heart rate, advancing age, higher blood pressure, female gender, and higher 
plasma renin activity are independent determinants of decreased HRV according to 
multivariate analyses combining hypertensive subjects and healthy controls. In a 
healthy middle-aged general population, psychological factors, particularly increased 
hostility and anxiety, and increased ambulatory pulse pressure are associated with 
reduced BRS and increased APV. Factors pertinent to the metabolic syndrome, such 
as higher levels of blood pressure, body fat percentage, insulin resistance, and serum 
triglycerides, are associated with decreased HRV and BRS and with increased APV. 
The exercise capacity had opposite associations with these parameters. Increased 
beat-to-beat variability of pulse pressure was related to several risk factors of arterial 
stiffening and to impaired BRS.
Measures of autonomic cardiovascular regulation are modulated by a complex 
interplay of several factors, and may also refl ect non-autonomic effects, such as those 
related to arterial stiffening.
Keywords: autonomic nervous system, barorefl ex, heart rate, blood pressure
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TIIVISTELMÄ
Autonomista kardiovaskulaarista säätelyä voidaan tutkia noninvasiivisesti syke-
vaihtelun ja baroheijasteherkkyyden avulla. Vaikka sekä sykevaihtelun että barohei-
jasteherkkyyden heikentymisen on todettu liittyvän epäsuotuisiin kardio vaskulaarisiin 
päätetapahtumiin useissa eri tutkimuksissa, näitä autonomisen hermoston toimintaa 
kuvastavia muuttujia määräävät tekijät tunnetaan huonosti.
Tässä tutkimuksessa selvitettiin autonomisten kardiovaskulaaristen muuttujien yh-
teyksiä elintapoihin, psyykkisiin tekijöihin, fyysiseen kuntoon, pulssipaineeseen, 
hypertensioon, ja muihin kardiovaskulaarisiin vaaratekijöihin. Menetelmänä käy-
tettiin syke- ja verenpainevaihtelun aika- ja taajuuskenttäanalyysejä sekä ristispektri-
menetelmään perustuvaa baroheijasteherkkyyden määritystä. Tutkimuksessa tarkas-
teltiin lisäksi pulssipaineen lyöntivaihtelua.
Sykevaihtelu todettiin pienentyneeksi keski-ikäisillä hypertensiivisillä henkilöillä. 
Monimuuttujamallissa sykevaihtelun pienenemistä selittivät itsenäisesti suurentu-
nut syketaajuus, ikääntyminen, kohonnut verenpaine, naissukupuoli sekä suurentu-
nut plasman reniiniaktiivisuus. Väestöotoksessa psyykkiset tekijät, erityisesti viha-
mielisyys ja ahdistuneisuus, ja ambulatorisen pulssipaineen suureneminen olivat yh-
teydessä pienentyneeseen baroheijasteherkkyyteen ja suurentuneeseen verenpaineen 
lyöntivaihteluun. Metaboliselle oireyhtymälle ominaiset tekijät, kuten suurentunut ve-
renpaine, kehon suurentunut rasvaprosentti, insuliini resistenssi sekä seerumin suuren-
tunut triglyseridipitoisuus, olivat yhteydessä sykevaihtelun ja baroheijasteherkkyyden 
pienenemiseen sekä verenpaineen lyöntivaihtelun suurenemiseen. Rasituksensiedon 
yhteys vasteisiin oli vastakkainen. Suurentunut pulssipaineen lyöntivaihtelu liittyi 
moniin valtimoiden jäykistymiseen yhteydessä oleviin vaaratekijöihin sekä huonon-
tuneeseen baroheijasteherkkyyteen.
Autonomiseen kardiovaskulaariseen säätelyyn vaikuttavat useat keskenään vuoro-
vaikutuksessa olevat tekijät. Todetut yhteydet saattavat kuitenkin selittyä osin mui-
denkin kuin autonomiseen hermostoon liittyvien vaikutusten kautta.
Avainsanat: autonominen hermosto, baroheijaste, sykevaihtelu, verenpaine
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ABBREVIATIONS
APV arterial pressure variability
BMI body mass index
BRS barorefl ex sensitivity
BSI-37 shortened 37-item version of the original 53-item Brief Symptom 
Inventory
DAP diastolic arterial pressure
ECG electrocardiogra|m, -phy, -phic
HDL high-density lipoprotein
HF high frequency
HOMA homeostasis model assessment
HRV heart rate variability
LDL low-density lipoprotein
LF low frequency
MSNA muscle sympathetic nerve activity
PP pulse pressure
PWV pulse wave velocity
RMSSD square root of the mean of squared differences between adjacent normal 
R-R intervals (ms)
SAP systolic arterial pressure
SD standard deviation
SDNN standard deviation of the normal-to-normal interval (ms)
STAXI Spielberger State-Trait Anger Expression Inventory
TAS-26 Toronto Alexithymia Scale
ULF ultra low frequency
VLF very low frequency
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1 INTRODUCTION
It is commonly perceived that a regular heartbeat is a sign of cardiac health. In truth, 
however, sinus rhythm, the rhythm of a healthy heart, is characterized by signifi cant 
variability. The purpose of dynamic beat-to-beat responses of heart rate and arterial 
pressure is to ensure sustained and appropriate perfusion to all tissues despite 
internal and external perturbations. The autonomic nervous system is one of the main 
mechanisms regulating circulatory homeostasis. Thus, high beat-to-beat variability 
of the heart rate is a sign of good adaptability, and implies that the person has well 
functioning autonomic control mechanisms. 
Heart rate variability (HRV) and barorefl ex sensitivity (BRS) have been used as simple, 
non-invasive techniques to examine autonomic cardiovascular nervous function. 
Depressed levels of HRV and BRS occur in a number of pathological conditions and 
predict cardiovascular morbidity and mortality (1–4). 
A major hurdle to the clinical use of HRV is that healthy subjects show wide 
interindividual variation in their heart rate behavior (5–7) and, despite more than three 
decades of research into HRV, the factors affecting heart rate dynamics are still poorly 
understood. Contradictory observations have been reported in many conditions, 
also systemic hypertension. There are only few studies examining the link between 
autonomic cardiovascular regulation and arterial stiffening and there is no data on 
the association between, on the one hand, pulse pressure (PP) and its beat-to-beat 
variability and, on the other hand, HRV and BRS. 
This thesis was set out to evaluate HRV in newly diagnosed, untreated hypertensive 
patients and healthy control subjects, and to assess the determinants of HRV in 
these populations. The present work also studied the relations between the measures 
of autonomic cardiovascular function and life style, psychological factors, PP, 
characteristics of insulin resistance, and physical fi tness in relatively healthy subjects 
of the general population. In addition, the beat-to-beat variability of PP and its 
associations with cardiovascular risk factors were investigated.
14
2 REVIEW OF THE LITERATURE
2.1 Anatomy and physiology of autonomic cardiovascular 
regulation
The heart rate is normally determined by depolarization of the sinoatrial node. 
The autonomic nervous system controls heart rate and blood pressure to maintain 
cardiovascular homeostasis. The autonomous nervous system can be divided into 
the sympathetic and the parasympathetic, also called the vagal, branches, which 
work in a coordinated way, usually reciprocally. Under resting conditions vagal tone 
prevails. The function of the autonomic nervous system is organized on the basis 
of a refl ex arch, which contains a visceral receptor, an afferent pathway, the central 
nervous system, an efferent pathway, and the effector organ. Inputs from systemic 
baroreceptors, cardiopulmonary low-pressure receptors, and chemoreceptors are 
coupled with a network of several cardiovascular and pulmonary regulation centers 
in the central nervous system. The efferent autonomic nerves consist of preganglionic 
and postganglionic neurons, which synapse in autonomic ganglia. The postganglionic 
fi bers innervate the effector organ. The output of this system is further modulated by 
neurohumoral and local factors. All parasympathetic and preganglionic sympathetic 
neurons are cholinergic; they release the neurotransmitter acetylcholine. The 
postganglionic sympathetic neurons are mainly adrenergic and release norepinephrine. 
The heart receives both cholinergic and adrenergic innervations, whereas the blood 
vessels are innervated mainly by adrenergic neurons. The autonomic nervous system 
has effects on heart rate, atrioventricular conduction velocity, myocardial contractility, 
coronary vasculature, and various cardiac electrophysiological parameters, including 
refractory periods, fi brillation-defi brillation thresholds, automaticity, and triggered 
activity after potentials.
2.2 Assessment of autonomic cardiovascular regulation
2.2.1 Assessment of heart rate variability
Quantifi cation of the heart rate period fl uctuations over time is termed HRV or R-R 
interval variability. Standardized electrocardiogram (ECG) acquisition conditions are 
crucial for the correct assessment of short-term HRV. The respiratory frequency of 
the subject should either be recorded or the breathing controlled at a frequency of 
15
12–15 breaths per minute. Continuous ECG signals are analogue-to-digital converted 
into a microcomputer to create a tachogram (Figure 1). Recorded data must be of 
good quality with minimal artifact. Proper visual inspection and processing of the 
recordings is essential, since ectopic beats, arrhythmic runs, noise artifacts, and 
missing data distort the analysis of HRV. 
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T i m e  d o m a i n  a n a l y s i s 
Time domain indexes of HRV evaluate oscillations of the heart rate as a function 
of time. They can be divided into statistical and geometric measurements (Table 1). 
The former are based on simple statistical analyses of successive R-R intervals or 
R-R interval differences. The major advantage of the latter is that it is relatively 
insensitive to artifacts and ectopic beats, while the major disadvantage is that rather 
long, preferably 24-hour, ECG recordings are needed (8). The most common time 
domain measure of HRV is the standard deviation of all normal-to-normal R-R 
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Table 1. Selected time domain indexes of HRV 
Statistical measures 
SDNN standard deviation of all N-N intervals (ms) 
SDANN standard deviation of the averages of N-N intervals in all 5 min segments of the 
entire recording (ms) 
SDNN index mean of the standard deviations of all N-N intervals for all 5 min segments of 
the entire recording (ms) 
pNN50 percentage of adjacent N-N intervals which differ by at least 50 ms (%) 
RMSSD the square root of the mean of the sum of the squares of differences between 
adjacent N-N intervals (ms) 
Geometric measures 
HRV triangular index total number of N-N intervals divided by the height of the histogram of all N-N 
intervals
TINN triangular interpolation of N-N intervals; width of the least square difference 
triangular interpolation of the N-N histogram 
Poincaré plot a plot of the current N-N interval (x axis) versus the subsequent N-N interval 
(y axis); also called Lorenz plot or return map 
N-N interval denotes normal-to-normal R-R interval. HRV, heart rate variability. 
intervals (SDNN). It refl ects overall HRV and is mathematically equal to the square 
root of the total power of HRV. The longer the recording period, the greater the SDNN. 
Therefore, 24-hour long-term or 5-minute short-term recordings have been preferred 
(8). In stationary short-term recordings, SDNN refl ects mainly the parasympathetic 
regulation of the heart rate (9). The most common measure derived from interval 
differences is the square root of the mean squared differences of successive normal-
to-normal R-R intervals (RMSSD). This measure of short-term variation refl ects fast 
parasympathetic regulation of the heart rate.
F r e q u e n c y  d o m a i n  a n a l y s i s 
A frequency domain analysis, also called power spectral density analysis, of the 
tachogram provides the basic information on how power, i.e. variance, is distributed 
as a function of frequency. In other words, the power spectrum refl ects the amplitude 
of the heart rate fl uctuations at different oscillation frequencies (10, 11). Frequency 
domain analysis of HRV is based on the assumption that the signal is stationary, 
i.e. statistically similar, over long periods. To increase stationarity, linear trends are 
removed by detrending and fi ltering the data before calculation of the power spectra. 
Frequency domain analysis can be performed by non-parametric fast Fourier transform, 
by parametric autoregressive modelling, and by wavelet decomposition (12). All 
these methods have their own advantages and disadvantages (8, 12). In practice, 
fast Fourier transform and autoregressive modelling are the most commonly used 
algorithms, and they yield practically comparable results (8, 9). Although frequency 
domain analysis can be used for the assessment of both short-term and long-term 
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recordings, frequency domain methods are particularly useful for the assessment of 
relatively short recordings. The duration of the recording should be at least 10 times 
the wavelength of the lower frequency bound of the spectral component investigated (8).
An example of a power spectrum of HRV is displayed in Figure 2. The recommended 
boundaries for the frequency bands are: total power < 0.4 Hz, high frequency 
(HF) 0.15– 0.40 Hz, low frequency (LF) 0.04– 0.15 Hz, very low frequency (VLF) 
0.003– 0.04 Hz, and ultra low frequency (ULF) < 0.003 Hz (8). These components 
estimate fl uctuations with a periodicity of roughly 2.5–6.6 s (HF), 6.6–25 s (LF), 
25 s–5 min (VLF), and > 5 min (ULF). Spectral components are reported either as 
arbitrary, i.e. absolute, units (ms2) or as normalized units, which usually represent the 
relative value of each power component in proportion to the total power minus the 
VLF component (%). The ULF and VLF components account for the majority of the 
total power of long-term recordings, but the problem of stationarity should be taken 
into account when analyzing them.
Respiratory sinus arrhythmia is the term used to describe the spontaneous fl uctuation 
of R-R interval with respiration. The heart rate accelerates during inspiration and 
decelerates during expiration. Respiratory oscillations of the heart rate arise from 
central mechanisms, and from the function of the barorefl ex in response to respiration-
synchronous fl uctuations in intrathoracic pressure, stroke volume, and arterial 
pressure. Respiratory sinus arrhythmia both buffers and contributes to respiratory 
arterial pressure fl uctuations.
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The HF component of HRV is equivalent to respiratory sinus arrhythmia at respiratory 
rates > 0.15 Hz (9 breaths/min). There is general agreement that it principally 
represents vagal modulation of heart rate in response to respiration (9, 11, 13–21). It 
correlates closely with vagally mediated time domain measures, such as RMSSD. A 
reduced breathing rate or increased respiratory tidal volume can raise the magnitude 
of the HF component of HRV (22, 23). However, respiratory sinus arrhythmia is not 
a purely vagal phenomenon (20, 21, 24, 25). The sympathetic neural outfl ow restricts 
respiratory sinus arrhythmia at rapid and at slow breathing frequencies (25), and there 
appears to be a purely mechanical portion of respiratory sinus arrhythmia (20, 25). 
A constant or saturated parasympathetic effect on the sinus node may reduce the HF 
component of HRV (26). Taken together, although the HF component of HRV can 
be used as an estimate of vagal modulation under standard physiological conditions, 
changes in these oscillations do not indicate vagal tone.
The LF oscillations of HRV may be generated by barorefl ex mechanisms (14, 27) 
or by a central oscillator control of the autonomic outfl ow (28, 29). Intrinsic neural 
rhythmicity may generate LF oscillations in tetraplegic patients (30) and in spinal 
sectioned decerebrate-vagotomized cats (31). Observations from anesthetized, 
vagotomized, sinoaortic denervated cats (32) and from patients with severe congestive 
heart failure treated with a left ventricular assist device (29) further indicate that LF 
oscillations do not depend on the functional integrity of barorefl ex mechanisms, 
although barorefl ex mechanisms account almost entirely for the LF component of 
HRV at supine rest (33).
The evidence for a link between LF oscillations in HRV and sympathetic excitation 
comes from experimental studies with denervated animals (16, 18, 34), and from clinical 
studies with various sympathetic stimuli (15, 16, 35) and direct microneurographic 
recordings of efferent muscle sympathetic nerve activity (MSNA) (35). However, 
there is no consistent relationship between LF oscillations and sympathetic outfl ow. 
The LF component of HRV is reduced in subjects with very high sympathetic activity, 
e.g. during strenuous exercise (36, 37) and heart failure (38, 39). Experiments with 
vagal denervated animals (13, 18) and parasympathetic blockade (11, 14, 15, 40) 
indicate that parasympathetic activity markedly contributes to the generation of 
LF variability of HRV. At supine rest, the LF component of HRV is mainly vagally 
controlled (15). Thus, the LF variability of HRV is mediated jointly by sympathetic 
and parasympathetic mechanisms. 
The VLF component has been linked to vascular α-adrenergic effector mechanisms 
(41), thermoregulation (10, 42), changes in peripheral chemoreceptor activity (43) and 
fl uctuations in activity of the renin-angiotensin-aldosterone system (11, 14, 40). It is, 
importantly, determined by vagal cardiac outfl ow (11, 14, 18, 40). Similar mechanisms 
to those responsible for the VLF component may be involved in the generation of the 
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ULF component. In long-term recordings, VLF and ULF fl uctuations of HRV depend 
mainly on physical activity (44). 
Some authors have proposed that the LF and HF components of HRV, expressed as 
normalized units, refl ect activities in the sympathetic and parasympathetic limbs of 
the autonomic nervous system, and that the LF/HF ratio of HRV provides an index 
of sympathovagal balance (16, 28). However, the sympathetic and parasympathetic 
nervous systems act in parallel in some situations, e.g. in cold immersion of the face. 
The idea of sympathovagal balance has been criticized by both mathematical and 
physiological arguments (45). 
N e w e r  m e t h o d s 
Conventional frequency domain methods regard the irregularity present in the heart 
rate signal as random noise. Fractal and nonlinear approaches have been adopted to 
evaluate irregular components in heart rate (46, 47). The word “fractal” refers to self-
scaling similarity over a wide range of scales. These newer methods are insensitive to 
changes in the external environment, such as the rate of respiration and physical activity, 
and they can produce information on heart rate dynamics. The Poincaré plot, or return 
map, is a graph in which each R-R interval is plotted as a function of the previous R-R 
interval (46). This geometric method provides a visual and quantitative analysis of R-R 
intervals. The techniques evaluating the fractal character of heart period include the
1/fβ decay of R-R interval spectral power in the logarithmic scale, detrended fl uctuation 
analysis, and coarse-graining spectral analysis (46, 47). Approximate entropy is one of 
the many nonlinear techniques which are based on nonlinear system or chaos theories 
(46, 47). Chaos refers to a system which has the characteristics of both periodicity 
and randomness. Approximate entropy measures the regularity and complexity of 
time series data by quantifying the likelihood that runs of patterns that are close to 
each other will remain close to each other in subsequent comparisons. Several studies 
suggest that heart rate nonlinear dynamics and fractal analysis may yield superior 
prognostic information compared to conventional measures of HRV in patients with a 
recent myocardial infarction or congestive heart failure (46).
In addition to fractal and nonlinear methods, there are other new approaches based 
on frequency domain analysis, e.g. assessment of the distribution of spectral power 
within the LF band (prevalent LF oscillation) (48) and of the variability of the phase 
shift between blood pressure and heart rate fl uctuations (49). These methods may help 
to stratify patients at risk of sudden cardiac death.
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2.2.2 Assessment of beat-to-beat arterial pressure variability
Non-invasive beat-to-beat measurement of fi nger arterial pressure is possible by a 
photoplethysmographic volume-clamp method (50). As illustrated in Figure 3, the 
same spectral components as those described for HRV are present in arterial pressure 
variability (APV) (14, 16, 34).
The HF oscillations of APV are related to respiratory activity. A substantial amount 
of these oscillations are caused by purely mechanical effects (17, 51), and, to a lesser 
extent, by vagally mediated R-R interval variability (17, 18, 51). 
The LF oscillations of arterial pressure are also known as vasomotor or Mayer waves 
(21). They are mainly under sympathetic control (18, 34, 35), but arterial barorefl exes 
also modulate them through a refl ex resonance loop involving sympathetic nervous 
activity and the vasculature (34, 52). The genesis of this variability is thus related to 
fl uctuations in vascular tone and peripheral resistance (53). The LF fl uctuations in 
arterial pressure persist during fi xed-rate atrial pacing (51). The structural changes 
within the vasculature or other mediators of vascular tone, such as angiotensin II, 
nitric oxide, and endothelial-derived vasodilators, may affect the LF oscillations in 
arterial pressure (21). The strength of the LF component in arterial pressure does not 
indicate mean sympathetic tone (21).
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The VLF component of APV has been related to α-adrenergic effector mechanisms 
(41, 53), the renin-angiotensin-aldosterone system (54) and the buffering effect of 
baroreceptor refl ex (52, 55). 
2.2.3 Assessment of barorefl ex function
The arterial barorefl ex buffers abrupt blood pressure changes. The arterial baroreceptors 
are stretch-sensitive nerve endings located primarily in the arterial wall of the carotid 
sinuses and the aortic arch. Activation of arterial baroreceptors by an increase in 
arterial pressure elicits refl ex parasympathetic activation and sympathetic inhibition, 
with subsequent decreases in heart rate, cardiac contractility, vascular resistance, 
and venous return. Conversely, a decrease in arterial pressure reduces baroreceptor 
discharge and triggers adjustments that, through increased sympathetic outfl ow and 
vagal withdrawal, counteract hypotension.
There are several methods to study barorefl ex responsiveness. Most commonly, these 
methods measure the response of the heart rate to arterial pressure changes, which are 
either spontaneous or induced by means of vasoactive agents (phenylephrine, sodium 
nitroprusside, nitroglycerin), the Valsalva maneuvre, external neck suction or neck 
pressure (56, 57). BRS is the slope of the linear relationship between R-R intervals and 
systolic arterial pressure (SAP). BRS refl ects the capacity of baroreceptor activation 
to increase vagal efferent activity. There are also newer methods to evaluate barorefl ex 
function, such as the barorefl ex effectiveness index (58) and the measurement of 
barorefl ex buffering function (potentiation of the pressor effect of phenylephrine 
during ganglionic blockade) (59).
Spontaneous fl uctuations of arterial pressure and of R-R intervals may be used to assess 
baroreceptor responsiveness in natural circumstances (57). In the sequence method, 
sequences of three or more beats, in which SAP spontaneously either increases or 
decreases and which are followed by parallel changes in the R-R interval, are identifi ed 
and barorefl ex slopes are determined. However, only a minority of progressive beat-
to-beat changes in SAP ramps are accompanied by barorefl ex-driven parallel changes 
in R-R interval ramps (58). In cross-spectral analysis of spontaneous baroreceptor 
responsiveness (27, 60), barorefl ex gain is calculated as the square root of the ratio 
between the R-R interval and SAP variabilities at the frequencies of physiological 
interest. Although there are several different calculations to estimate cross-spectral 
BRS (61), this variable is often determined only if the two signals show high coherence 
(> 0.5) and if arterial pressure changes precede, i.e. phase is negative, R-R interval 
changes (Figure 4). The drawback of this method is that all subjects do not express 
coherent fl uctuations between R-R intervals and SAP, and it is not known whether this 
absence of coherence has prognostic implications. While traditional techniques might 
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be used to explore the entire stimulus-response curve of baroreceptors, spontaneous 
techniques provide information on the regulatory infl uence of barorefl ex acting around 
its set point. Despite this difference, BRS measures calculated with the sequence 
method (62) and the cross-spectral method (60, 63) correlate reasonably well (r from 
0.6 to 0.9) with those of phenylephrine method.
2.2.4 Other techniques to evaluate autonomic cardiovascular function
Traditional clinical tests of autonomic cardiovascular function use the response of 
the heart rate to deep breathing, a Valsalva maneuvre or postural change to examine 
vagal cardiac function. Cardiovascular sympathetic function is assessed by evaluating 
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ranges have also been listed. BRSc, baroreflex sensitivity calculated from
frequency ranges showing coherence >0.50; BRScp, baroreflex sensitivity
calculated from those frequency ranges which show coherence >0.50 and a
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the blood pressure response to active standing, passive tilting, a Valsalva maneuvre, 
sustained handgrip or cold water immersion (64). 
Cardiovascular sympathetic function has also been evaluated with a number of other 
methods (65), including hemodynamic measurements, adrenergic and ganglionic 
pharmacological blockade, plasma levels of norepinehrine (66, 67), plasma 
norepinephrine kinetics (regional norepinephrine spillover measurements) (68, 69), 
microneurography (69, 70), and radionuclide imaging techniques (71). There is no 
correlation between the LF component of HRV and cardiac norepinephrine spillover, 
which provides a cardiac-specifi c measure of sympathetic nerve fi ring rate (69). 
Generally speaking, no single measurement of HRV correlates well with sympathetic 
activity.
Heart rate turbulence describes the response of the heart rate to the fall in blood 
pressure that follows a premature ventricular ectopic beat. This results in deceleration 
of the sinus rhythm after an initial acceleration. Turbulence onset expresses the relative 
shortening of R-R intervals immediately after the compensatory pause. Turbulence 
slope expresses the slope of the linear regression line between R-R interval count 
and R-R interval duration during the subsequent lengthening of R-R intervals (72). In 
subjects with congestive heart failure, heart rate turbulence correlates strongly with 
a standard measure of BRS (73). The absence of heart rate turbulence is a strong 
predictor of mortality of patients who have had a myocardial infarction (74).
2.2.5 Reproducibility of methods evaluating autonomic cardiovascular 
function on a beat-to-beat basis
Although HRV is commonly regarded as a reliable technique, this assumption may 
be a gross oversimplifi cation (75). The reproducibility of HRV is dependent on a 
number of factors, including the measured variable, the study population, the length 
of the recording, the time of the day, and the stability of the recording conditions. In 
short-term measurements, it is crucial to standardize the recording conditions and 
control the breathing rate of the subject to increase the reliability of the results (8). 
Despite considerable intraindividual day-to-day variations especially among healthy 
subjects, mean group values for HRV between subsequent recordings correlate well 
(r ≥ 0.87) (76). In a study examining the reliability of spectral indexes of HRV from 
5-minute recordings obtained 2 months apart in women and men aged 35–65 years 
(77), the correlation coeffi cients ranged from 0.64 to 0.82 under metronomic breathing 
and from 0.65 to 0.75 under free breathing. The spontaneous BRS method is also 
satisfactorily reproducible (r from 0.54 to 0.87) (78). The repeatability of short-term 
beat-to-beat APV has not been documented.
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2.3 Autonomic cardiovascular regulation in healthy subjects
2.3.1 Autonomic function in relation to changes in body posture and 
activity
Parasympathetic activity is attenuated upon standing, and this results in reduced 
arbitrary or normalized HF components of HRV (15, 16, 79, 80). Simultaneous 
augmentation in sympathetic activity may increase the LF component, expressed 
in arbitrary or normalized units, and the LF/HF ratio (15, 16, 79, 80). The results 
concerning the overall variability of HRV in response to standing are variable (16, 
79, 81).
Autonomic activity follows a circadian rhythm: the sympathetic tone increases on 
wakening and the parasympathetic tone at night. In the frequency domain, the total 
(6, 82) and HF powers (82–84) of HRV are higher during night-time than during 
daytime. The LF/HF ratio follows also a circadian pattern: values are lowest at night 
and highest during the day (82, 84). 
Traditional measures of HRV do not accurately refl ect changes in autonomic modulation 
during exhaustive exercise. Consistent with the rapid withdrawal of vagal activity, the 
HF component of HRV decreases at the onset of exercise (36, 37). However, heavy 
exercise may decrease also the total and LF powers of HRV (36, 37). With increasing 
exercise intensity, the LF/HF ratio does not increase but rather decreases (37) or 
remains at a level that is lower than at rest or during recovery (36). 
There are also several other factors which may cause intraindividual variation in 
autonomic activity and which should be controlled during short-term recordings of 
HRV, e.g. respiration (22, 23), mental and verbal activities (85), food intake (86), and 
room temperature (87). In menstruating females, cardiac vagal tone is higher in the 
follicular phase than in the luteal phase (88). In long-term recordings, the time domain 
indexes and the VLF and ULF components of HRV depend largely on the amount of 
physical activity (44).
2.3.2 Interindividual variation of autonomic cardiovascular function
Healthy subjects show marked interindividual variation in the measures of autonomic 
function (5–7). The major determinant of HRV is the basal heart rate (89, 90) which 
itself is modulated by autonomic cardiovascular regulation. The heart rate is also 
inversely related to BRS (91, 92). 
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A g i n g
HRV gradually increases during childhood (93). Despite lower time and frequency 
domain measures of HRV, children show similar complexity and fractal correlation 
properties as young adults (94). Healthy aging is associated with a decline in HRV 
(90, 93–98), a loss of fractal scaling properties, and reduced complexity of heart rate 
dynamics (94). Parasympathetic indexes of HRV decline earlier and more rapidly 
(93, 96, 97). Age is an independent determinant of HRV in studies with multivariate 
analysis (83, 89, 98). Also BRS decreases with aging (91, 92, 99–101). The relationship 
between age and beat-to-beat APV is less clear (101), although some associations 
with age have been observed (102, 103).
G e n d e r
Overall, the HRV (90, 95, 98, 104) and BRS (91, 92, 105) of females is lower than of 
males. The LF power of HRV, expressed as arbitrary or normalized units, (80, 90, 95, 
97, 98, 105, 106) and the LF/HF ratio (80, 90, 95, 97, 98, 105, 106) are lower, and the 
HF power, expressed as arbitrary or normalized units, is higher (80, 97, 105, 106) or 
similar (90) in women compared to men. The circadian profi le of the LF component 
of HRV has been reported to differ between sexes, men having the highest level in the 
morning and afternoon, and women in the afternoon and evening (107). The gender 
infl uences on HRV disappear after age 40–60 years (90, 96, 97, 106), and BRS may 
even be higher in women after age 60 years (92). The mechanisms of gender-related 
differences are not precisely known, but seem to be related to female sex hormone 
production.
L i f e s t y l e
Many lifestyle factors affect autonomic cardiovascular function. An acute intake 
of alcohol (108, 109) or caffeine (110, 111), and smoking a cigarette (112) reduce 
parasympathetic measures of HRV and BRS. Results from the studies evaluating the 
long-term infl uences of smoking, coffee drinking, and alcohol consumption on autonomic 
function are inconsistent and may be modifi ed by the environmental and cultural factors 
(80). In some cross-sectional studies, alcohol consumption (7, 89, 98), coffee intake 
(80, 89), and smoking (7, 83, 89, 98, 104, 113) have been related to HRV changes 
implying reduced vagal or increased sympathetic modulation. There is an improvement 
in HRV after cessation of smoking (114). Higher alcohol consumption and smoking 
have also been linked with a decrease in BRS (92). Alcoholics appear to have reductions 
in principally parasympathetic indexes of HRV (108) and in BRS (115). 
Trained athletes have high parasympathetic activity, which is partly responsible for 
the sinus bradycardia so common among athletes. If overtraining conditions are 
excluded (116), the vagally mediated measures of HRV are higher in athletes than in 
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non-competitive healthy subjects (12). Some cross-sectional studies have related HRV 
indexes with functional capacity or physical training level (83, 97, 98, 117). Fitness 
has also been related to higher BRS (100, 118). Although there are discrepancies 
(12), exercise training seems to increase HRV, to augment barorefl ex function, and to 
decrease MSNA in sedentary healthy subjects (119–121). 
There is no conclusive information on associations between salt intake and autonomic 
function, although one would expect such associations to exist. Omega-3 fatty acid 
supplementation increases the HF component of HRV in patients with a history of 
myocardial infarction (122). 
C l i n i c a l  a n d  l a b o r a t o r y  m e a s u r e s
Many other clinical and laboratory parameters have been related to autonomic 
cardiovascular function in healthy subjects. Serum triglycerides (104, 113, 117, 123), 
total cholesterol (124) and low-density lipoprotein (LDL) cholesterol (7, 124) are 
inversely related to HRV, whereas a direct association may exist between high-density 
lipoprotein (HDL) cholesterol and HRV (104, 123). Uric acid (98) and microalbuminuria 
(117) have also been associated with impaired autonomic cardiovascular function. 
Recent studies have related reduced HRV to increased levels of infl ammation markers, 
such as leukocyte count (104), C-reactive protein concentration (98, 113, 125), 
interleukin-6 (126, 127), and tumor necrosis factor (128), in general population or in 
apparently healthy subjects (98, 104, 113) and in patients with stable coronary heart 
disease (126), acute coronary syndrome (125), or congestive heart failure (127, 128). 
Some other associations are mentioned in the context of hypertension and insulin 
resistance in this review.
H e r i t a b i l i t y
There are racial differences in autonomic cardiovascular function (129, 130). In a 
large study involving 772 healthy twins and singleton siblings, multivariate genetic 
analyses suggested that genetics explain 35–48% of the variance in time domain 
HRV parameters (131). In the Framingham heart study, heritability was estimated 
to account for 13–23% of the variation among HRV measures (132). BRS is also 
strongly infl uenced by genetic factors (133, 134).
2.4 Psychological factors and autonomic cardiovascular regulation
The interest of scientists in the relationship between psychological factors and autonomic 
nervous system function originates in an effort to identify the physiologic parallels of 
psychiatric illness, and to discover possible mechanisms how psychological conditions 
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affect the pathogenesis and progression of cardiovascular diseases. Anxiety, anger, 
depression, and possibly even other negative psychological states have been linked 
to the development of hypertension (135) and to the risk of coronary heart disease 
(136, 137). Depression has also been related to increased cardiovascular mortality and 
morbidity among patients with coronary heart disease (138). While exact mechanisms 
underlying these associations are poorly understood, both direct biological and indirect 
behavioral effects are involved. In addition to autonomic nervous dysfunction, other 
direct mechanisms that may be involved include neuroendocrine activation, platelet 
and blood coagulation abnormalities, and vascular effects, e.g. infl ammatory activation 
and endothelial dysfunction (136).
A n x i e t y  d i s o r d e r s
Research into the relationship between anxiety disorders and autonomic cardiovascular 
function has mostly evaluated patients with panic disorder. Mixed results have been 
reported, including no changes (67, 139, 140), decreases in overall variability (141–
143) and vagal (142, 144) indexes of HRV, and increases in sympathetic indexes 
of HRV (142, 144, 145). Further proof against sympathetic activation comes from 
studies showing that norepinehrine spillover and MSNA values are within the 
reference ranges (144, 146, 147). One of these studies evaluated also the neuronal 
reuptake of noradrenaline in the heart and found that it is impaired in panic disorder 
patients (144). However, the studies performed outside panic attacks cannot exclude 
the possibility that patients with panic disorder might display a state of sympathetic 
overactivity during acute episodes. Relatively few studies in patients with generalized 
anxiety disorder (148), blood phobia (142), or posttraumatic stress disorder (145) 
suggest that the overall variability or vagal indexes of HRV may be reduced in these 
disorders, possibly, with a concomitant relative increase in sympathetic modulation in 
the posttraumatic stress disorder. 
D e p r e s s i v e  d i s o r d e r s
While one study observed reduced vagal indexes compared to controls in patients with 
major depressive disorder (149), others have not reported differences (139, 150–155) 
in HRV at supine rest. Similarly, BRS is impaired in patients with major depressive 
disorder according to some (150, 156) but not all (153, 157) studies. Contrary to these 
mainly negative results in major depressive disorder, most studies in various coronary 
heart disease populations indicate that HRV and BRS are lower among depressed than 
non-depressed patients (158–163). No differences have been detected in the beat-to-
beat variability of SAP between depressive and non-depressive patients (150, 157, 
158).
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P s y c h o l o g i c a l  f a c t o r s  i n  s u b j e c t s  w i t h  n o  p s y c h i a t r i c 
d i s o r d e r s
Subjects with no psychiatric disorders have been examined with regard to any 
relationships between psychological factors and autonomic cardiovascular regulation. 
Both positive and negative emotions affect measures of HRV in short-term recordings 
(164). The indexes that mainly refl ect vagal modulation are lower in subjects with 
anxiety than in healthy persons (165–168). In hypertensive subjects, anxiety has 
been related to a decrease in the HF component of HRV and to an increase in left 
ventricular mass (168, 169). Studies examining hostility, anger expression, or type 
A personality imply that there is an increased sympathovagal balance (170, 171) or 
a reduction in the parasympathetic measures of HRV (171, 172). One study found an 
association between coping style, the way people cope with stressors, and HRV in men 
but not in women (173). Perceived psychosocial stress has been related to increased 
sympathovagal balance (174, 175). Asymptomatic coronary artery calcifi cation 
correlated independently in postmenopausal women with a greater reduction in the 
HF component of HRV in response to a psychosocial stressor (176). Alexithymia, a 
marked diffi culty in describing and expressing feelings, has been related to an increase 
in the LF/HF ratio (177). Finally, depressive symptoms have been related to a decrease 
in HRV among college students (178) and postmenopausal women (179). There are 
no population-based studies on the relationship between psychological factors and 
autonomic activity. 
The data on the relationship between psychological factors and BRS or beat-to-beat 
APV are scant. The few studies that are available suggest that anxious subjects may 
have lower BRS (166) and a higher LF component of SAP variability than non-
anxious controls (167). Psychosocial stress may also decrease BRS and increase the 
LF component of SAP variability (175).
2.5 Effects of drugs and somatic illness on autonomic 
cardiovascular regulation
2.5.1 Effects of drugs on autonomic cardiovascular regulation
Many drugs interfere with autonomic cardiovascular function either directly or 
indirectly. Some drugs affect central sympathetic outfl ow, alter barorefl ex control 
of sympathetic motoneurons or interfere with norepinephrine release at sympathetic 
neuroeffector junctions (180). The indirect drug effects may be secondary to drug 
actions on arterial wall properties or hemodynamics, or, in the long term, result from 
the reversion of structural changes in the large arteries or from the regression of left 
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ventricular hypertrophy. The cardioprotective effects of some drugs may at least partly 
be based on their effects on autonomic cardiovascular control. 
β-receptor blocking agents enhance HRV and BRS also in healthy subjects (98, 181, 
182). Their effect is most marked on the measures of vagal activity. Despite some 
initial observations on dogs (14) and subsequent fi ndings in studies on healthy young 
subjects (40) according to which blockade of angiotensin-converting enzyme (ACE) 
induces a modest increase in the VLF power of HRV, there are no uniform data on the 
effects of ACE-inhibitors and angiotensin 1 receptor antagonists on HRV and BRS 
(98, 183–185). The effects of ACE inhibitors and angiotensin 1 receptor antagonists 
on autonomic measures may depend on the state of activation of the renin-angiotensin-
aldosterone system. For example, BRS is improved in sodium-depleted but not in 
sodium-replete subjects (185–187). The indirect mechanisms related to hemodynamic 
improvement and the regression of left ventricular hypertrophy are probably crucial 
for the effects of ACE inhibitors and angiotensin 1 receptor antagonists on autonomic 
measures (188, 189).
Other drugs that produce favorable changes in HRV or BRS include aldosterone 
antagonists (190), digoxin (183), verapamil (191), statins (192), estrogen replacement 
therapy (193), and anticholinergic muscarinic blockers at low doses (194). On the other 
hand, class IC antiarrhythmic drugs (195), short-acting nifedipine (196), nitroglycerin 
(197), and diuretics (98) are associated with a decrease in HRV or BRS. Tricyclic 
antidepressants reduce HRV markedly (149, 151, 198). Although selective serotonin 
reuptake inhibitors are usually considered safe drugs for the heart (198), one study 
reported that they might reduce HRV (155). Diltiazem, slow-releasing nifedipine 
formulations, and dihydropyridine derivatives with a long half-life (181, 196, 199, 
200) do not have major effects on HRV according to most studies. Concerning the 
effects of centrally acting antihypertensive drugs (α2- and imidazoline (I1)-agonists) 
and α1-adrenergic receptor antagonists, results are inconsistent or lacking.
2.5.2 Autonomic cardiovascular regulation in systemic hypertension
Research on the role of the autonomic nervous system for the development of 
hypertension was stimulated by observations that early in hypertension hemodynamics 
are hyperkinetic (201). Early research also indicated that increased sympathetic tone 
is coupled with reduced parasympathetic activity in borderline hypertension (202). 
Thereafter, studies with several experimental methods, including plasma norepinehrine 
levels (66), direct microneurographic recordings (70), and norepinephrine spillover 
(68), have suggested that at least a subgroup of hypertensive subjects has increased 
sympathetic tone. HRV studies suggest that a low HRV predicts a greater risk of 
incident hypertension (203–205).
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In the rather few studies on HRV in borderline hypertensive subjects, there have been 
no differences between borderline hypertensive and normotensive subjects (206–
209). Despite similar HRV, the VLF component (208) or all the components (207) of 
beat-to-beat APV have been increased in borderline hypertensive subjects compared 
with normotensive controls (207, 208) and hypertensive subjects (208). Borderline 
hypertensive subjects had have attenuated night-day variation in the VLF component 
of APV (208). Their median frequency of LF oscillations may be shifted to lower 
frequencies (210), which may predict progression to sustained hypertension (211). A 
reduction in BRS occurs in individuals with high normal blood pressure (212).
HRV in patients with sustained essential hypertension varies. The early study of Pagani 
and coworkers found that hypertensive subjects had a higher peak in the LF band at 
rest, and they were unable to further increase it with tilting (213). Later, scientists at 
the same department published an article where they did not report spectral powers in 
arbitrary units at all, but claimed that untreated hypertensive subjects had a decreased 
HF component and an increased LF component of HRV, expressed as normalized units, 
and an increased LF/HF ratio (206). These fi ndings were interpreted by the scientists 
as suggesting increased sympathetic activity in essential hypertension. Subsequent 
studies comparing untreated hypertensive and normotensive individuals have found 
that the normalized LF component of HRV is similar (214, 215), higher (216–218) or 
age-dependent (219), i.e. higher in young and middle-aged but not in elderly people. 
Similarly, the LF/HF ratio has been reported to be higher (216–218, 220), similar 
(203, 204, 214, 221), or age-dependent (219) in hypertensive subjects.
Data concerning the parasympathetic cardiovascular regulation in hypertension are 
more concordant. Although there are studies that have not demonstrated differences in 
HRV between untreated hypertensive and normotensive subjects (208), most studies 
have found either decreases in the vagal indexes of HRV (218, 220) or an overall 
reduction in HRV (203–205, 215, 217, 219, 222). The circadian rhythm of HRV is 
altered in hypertensive subjects (223, 224), and the changes in HRV are blunted in 
response to an upright position (206, 214, 216, 221, 225). However, these fi ndings 
have not been confi rmed in all studies (208, 226, 227).
Ambulatory blood pressure variability is greater in hypertensive than normotensive 
subjects (228). Explored by frequency domain, beat-to-beat APV has been similar 
(208, 214) or increased in the total (175), LF (175, 222, 229) and HF powers (175). 
Similarly, both normal responses (208, 214) and blunted increases in the LF component 
of APV (229) in response to an upright posture have been reported in hypertensive 
subjects. The etiology and severity of hypertension, and secondary adaptive processes 
during the course of hypertension may infl uence beat-to-beat APV. Increased beat-to-
beat APV was not observed in patients with left ventricular hypertrophy (222). Severe 
renovascular hypertension has been associated with a decrease in beat-to-beat APV 
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(230). BRS is decreased in hypertensive subjects (133, 222, 231–234), and it may be 
one of the mechanisms which result in increased fl uctuations of SAP variability. 
2.5.3 Autonomic cardiovascular regulation in insulin resistance
In the general population, the body mass index (BMI) and the waist-to-hip ratio 
correlate negatively with HRV (104, 117, 235) and BRS (92, 100, 235), and positively 
with the LF/HF ratio of HRV (80). Obese normotensive subjects have reduced HRV 
(236–239) and BRS (238, 240, 241), and their beat-to-beat APV (237) and MSNA 
(242–244) are increased. In euglycemic-hyperinsulinemic clamp studies, the LF/HF 
ratio of HRV has been higher in obese subjects than in lean subjects at baseline, and it 
remained unchanged or increased less after insulin in obese subjects than lean subjects 
(236, 245). Weight gain reduces the HF component of HRV (246). Conversely, weight 
loss increases HRV (239, 247), augments barorefl ex function (248), and reduces 
MSNA (248), which is consistent with augmented parasympathetic and suppressed 
sympathetic control of the heart rate.
In the general population, fasting insulin, glucose, or glycosylated hemoglobin (117, 
249, 250) correlate inversely with HRV. These factors are also negatively associated 
with BRS in healthy volunteers (100). Autonomic dysfunction deteriorates as the 
impairment of glucose metabolism advances (235, 250, 251). Also, subjects with low 
levels of HRV have an increased risk of diabetes (252).
Diabetes mellitus, even uncomplicated, is associated with reductions in all spectral 
components of HRV (89, 249, 250, 253), an increase in the LF component of SAP 
variability, and a decrease in BRS (253). Overt clinical neuropathy results in further 
impairment of autonomic cardiovascular function, and measures of HRV and BRS 
have been applied for the early detection of autonomic neuropathy associated with 
diabetes (254, 255). Impaired HRV predicts coronary heart disease (256) and increased 
mortality (257) among diabetics. Improvements in HRV have been reported after strict 
glycemic control, lifestyle modifi cation, and metformin administration (258–260).
The metabolic syndrome, the insulin resistance syndrome, or syndrome X is a cluster of 
coronary heart disease risk factors with insulin resistance as the common denominator. 
It is associated with hypertension, visceral obesity, glucose intolerance, a low level 
of HDL cholesterol, and a high triglyceride level. Although insulin resistance is 
generally considered to be linked with enhanced sympathetic drive, it is not known 
whether insulin resistance represents the initial defect that activates the sympathetic 
nervous system or whether the primary defect is an increase in sympathetic nervous 
system activity.
Enhanced sympathetic drive may contribute to several components of the metabolic 
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syndrome. Insulin shifts cardiac sympathovagal balance towards sympathetic 
predominance. It stimulates a decrease of the HF and LF components expressed in 
arbitrary units (236) and an increase in the LF/HF ratio of HRV (236, 245) and in 
MSNA (261). Also leptin has been related to enhanced sympathetic drive (262). In 
hypertensive subjects, insulin sensitivity has been related to HRV (263). One study 
found that changes in HRV and BRS emerged only in those hypertensive subjects 
who also had the metabolic syndrome (264). Research on abdominal-to-peripheral 
fat distribution suggests that HRV and BRS are reduced more (241, 265) and MSNA 
is increased more (242, 244) in visceral obesity than peripheral obesity. Insulin 
resistance is associated with autonomic dysfunction also in subjects with normal 
glucose tolerance (235, 251).
Risk factors that are associated with insulin resistance cluster around a reduction in 
HRV (117). HRV is decreased (266) and MSNA is increased (267, 268) in patients 
with the metabolic syndrome. Higher levels of fasting insulin and insulin resistance, 
calculated by the homeostatis model assessment (HOMA), are inversely related 
with HRV and BRS (269, 270) and directly to MSNA (262, 268). HRV and BRS are 
inversely associated with the number of components of the metabolic syndrome (269, 
270). In agreement with this, the presence of hypertension and obesity (240) or the 
metabolic syndrome in the same subject (267, 268) is associated with a further increase 
in MSNA compared with either condition alone. This suggests a greater sympathetic 
activation when multiple components of the metabolic syndrome are present. 
2.5.4 Autonomic cardiovascular regulation in cardiac diseases
Autonomic cardiovascular function is abnormal in various cardiac diseases. HRV is 
reduced in asymptomatic patients with coronary artery calcifi cation (117). HRV and 
BRS are decreased in patients with coronary heart disease (4, 271), especially after 
myocardial infarction, and in patients with congestive heart failure (39, 271, 272). 
Reduced HRV may predict the development and progression of coronary heart disease 
(4). Several parameters refl ecting the severity of congestive heart failure (273, 274) and 
the angiographic severity of coronary heart disease (275) are related to HRV. Changes 
in autonomic nervous cardiac activity may precede ventricular tachyarrhythmias 
(276, 277). Most importantly, impaired HRV may predict mortality, particularly in 
patients who have had a myocardial infarction (1, 4) and in patients with congestive 
heart failure (272, 278). BRS has also been used to risk stratify postinfarction patients 
(279). 
Alterations in autonomic cardiovascular function are also related to various other 
cardiac diseases, including cardiac syndrome X (280), vasospastic angina (281), 
chronic severe mitral regurgitation (282), and idiopathic dilated cardiomyopathy 
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(283). HRV is markedly reduced after cardiac transplantation, but cardiac sympathetic 
nerve function is partially restored over time (284). Autonomic modulation may be 
associated with initiation and recurrence of atrial fi brillation and atrial fl utter (285–
288). HRV does not improve the predictive accuracy of established arrhythmic risk 
factors in patients with hypertrophic cardiomyopathy (289). 
Despite several studies confi rming that HRV and BRS provide information on the 
risk of subsequent death in various populations, including the general population (2, 
3, 290), autonomic tests are not applied in clinical practices. This is due to several 
circumstances. First, the mechanisms of this association are largely unknown and there 
is, secondly, no specifi c therapy available to improve the prognosis. Thirdly, there 
is no consensus on the best way to measure HRV for clinical purposes. Further, no 
single test is alone satisfactory for predicting the risk of major arrhythmic events. And 
fi fthly, the value of autonomic risk markers for predicting sudden death has become 
somewhat blurred with the widespread use of statins and medications resulting in 
a more comprehensive blockade of β-adrenergic and renin-angiotensin-aldosterone 
systems (291).
2.5.5 Autonomic cardiovascular regulation in non-cardiac diseases
In addition to structural heart diseases, there are numerous reports linking altered 
HRV to various non-cardiac diseases, e.g. end stage renal disease (292), chronic liver 
disease (293), hypoxia in chronic respiratory disease (294), obstructive sleep apnea 
(215, 295), disorders of the nervous system (296), anemia (297), systemic diseases 
like amyloidosis (298), and severe infections (299).
2.6 Pulse pressure and arterial stiffening
PP arises from the interaction between the left ventricular stroke volume and the 
characteristics of the arterial circulation that determine compliance and wave refl ection 
(300). PP is a surrogate marker for arterial stiffness. Elevated PP is related to increased 
left ventricular and arterial wall thickness and to cardiovascular events and mortality 
(300). There is a vicious cycle between PP and atherosclerosis: a high PP promotes 
atherosclerosis, which results in large-vessel stiffening and increased wave refl ection, 
thus further amplifying PP. Although there is high colinearity between PP and systolic 
blood pressure, PP can be a superior predictor of cardiovascular risk compared with 
systolic, diastolic, or mean blood pressures, at least in the elderly (301).
Aging is associated with a loss of arterial elasticity. Arterial stiffness is also related to 
several cardiovascular risks, such as hypertension, obesity, metabolic syndrome, and 
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diabetes (302). Several devices and methods have been developed to quantify arterial 
stiffening in humans (303). The intima-media thickness, arterial compliance, and 
arterial distensibility can be determined by sonographic evaluation of the common 
carotid artery. While arterial compliance denotes absolute diameter or area change for 
a given pressure increment, arterial distensibility refers to the corresponding relative 
changes. Special instrumentation can be used to quantify pulse transit time and to 
analyze the wave contour of the arterial pulse. Pulse wave velocity (PWV) (i.e. the 
velocity of the pulse wave along the arterial tree) increases as the stiffness of the 
arterial system increases. Increases in PWV may also be due to increased sympathetic 
tone (152). Arterial stiffness affects pulse wave refl ection and pulse wave analysis 
can be used to detect resultant alterations in pressure wave contour. For example, 
young subjects have high pressure wave augmentation, which results in progressive 
elevation of systolic blood pressure in peripheral arteries. In older subjects, the more 
rapid propagation of the pulse wave reduces pressure wave augmentation and this 
results in nearly identical central and peripheral blood pressures (302). 
There are only few studies that have examined associations between autonomic 
cardiovascular function and arterial stiffening. The PWV correlates positively with the 
LF/HF ratio and negatively with the HF component of HRV in young male subjects 
(304). In middle-aged healthy men, PWV correlates inversely with HRV (305). PWV 
and arterial compliance measurements are also related to HRV in type 1 diabetics 
(306, 307). A lower pulse transit time and a higher PWV have been associated with 
reduced BRS in stroke and chronic hemodialysis patients (308, 309).
2.7 Summary
HRV and BRS convey prognostic information, especially of subjects who have had 
a myocardial infarction. However, there is substantial interindividual variation in the 
measures of autonomic function, and apart from cardiac disease, numerous lifestyle-
related, physiologic, psychological, and hereditary factors, as well as medications 
affect these indexes. A complex interplay among these factors that is currently not 
well understood may explain a part of the confl icting results from studies evaluating 
determinants of autonomic cardiovascular regulation. This thesis is an effort at 
clarifying the above issues. 
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3 AIMS OF THE STUDY
The aims of the present study were to examine the abnormalities of autonomic 
cardiovascular regulation of patients with untreated hypertension and to evaluate the 
determinants of the beat-to-beat R-R interval, SAP, diastolic arterial pressure (DAP), 
and PP variabilities, and of BRS, in middle-aged subjects. The specifi c goals were:
1 to compare the measures of HRV in newly diagnosed, untreated hypertensive 
patients and control subjects, and to assess the determinants of HRV in these 
populations (I) 
2 to study the associations between psychological factors and autonomic cardio-
vascular regulation in a healthy middle-aged population through spectral analyses 
of the beat-to-beat R-R interval, SAP, and DAP variabilities, and BRS (II)
3 to test whether PP is associated with autonomic cardiovascular regulation in 
two apparently healthy middle-aged populations as assessed by the beat-to-beat 
R-R interval and SAP variabilities and BRS (III)
4 to examine the beat-to-beat PP variability and its associations with PP and 
risk factors for atherosclerosis and arterial stiffening in a healthy middle-aged 
population (IV)
5 to evaluate the effects of glucose and lipid metabolism, body fat composition, 
lifestyle factors, and physical fi tness on autonomic cardiovascular regulation in 
a healthy middle-aged population (V)
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4 MATERIALS AND METHODS
Three populations were examined (Figure 5). Populations 1 and 2 included randomly 
chosen age- and gender-stratifi ed apparently healthy subjects. Population 3 consisted 
of patients with recently diagnosed, untreated hypertension.
4.1 Study populations
4.1.1 Population 1
Population 1 consisted of an age- and gender-stratifi ed random sample of 45 subjects 
of both genders and each 10-year age group (35– 44, 45–54, and 55–64), selected 
from the national population register of inhabitants residing in the vicinity of Turku in 
southwestern Finland. Subjects with coronary artery disease, congestive heart failure, 
previous cerebrovascular event, claudication, hemodynamically signifi cant valvular 
disease, severe anemia (hemoglobin < 110 g/l for men and < 100 g/l for women), 
chronic alcoholism, diabetes mellitus, or confounding medication were excluded 
based on medical history, clinical examination, routine biochemical tests, exercise 
EGG, and echocardiographic examination. Medications resulting in exclusion 
included all ordinary cardiovascular drugs, β-blocker eye drops, teophyllamine, 
β2-sympathomimetics, and antineoplastic drugs, and in studies II–V, additionally, 
antidepressants and neuroleptics. For the control group of newly diagnosed hypertensive 
patients (i.e. population 3) in study I, subjects aged 35–54 were selected, and those 
with a systolic or diastolic blood pressure of ≥ 140 or ≥ 90 mm Hg, respectively, 
were excluded. After further exclusion of subjects who did not complete the studies, 
inadequate ECG, or ambulatory blood pressure recordings, the fi nal analyses included 
105 subjects (56 women and 49 men) in study I, 149 subjects (78 women and 
71 men) in study III, and 150 subjects (79 women and 71 men) in studies II, IV, and 
V. The studies were conducted following the Second Declaration of Helsinki and were 
approved by the Ethics Committee of the Social Insurance Institution of Finland. All 
subjects gave written informed consent.
4.1.2 Population 2
Population 2 (III) consisted of an age- and gender-stratifi ed random sample of 300 men 
and 300 women, aged 40–59 years, selected from the register of the Social Insurance 
Institution of the inhabitants of Oulu in northern Finland for OPERA (Oulu Project 
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Elucidating Risk of Atherosclerosis), an epidemiological study of cardiovascular risk 
factors (19). This population was examined only in study III. After application of 
exclusion criteria, similar to those used for population 1, the fi nal analyses included 
214 subjects (126 women and 88 men). Informed consent was obtained of each 
subject, and the protocol was approved by the Ethics Committee of the University of 
Oulu.
4.1.3 Population 3
Population 3 (I) was drawn from the city of Turku and three neighboring municipalities 
in southwestern Finland. It consisted of 249 moderately to severely hypertensive 
white men and women, aged 35–54 years. They had newly diagnosed, untreated 
hypertension. The inclusion criteria were a systolic or diastolic blood pressure 
consistently in the range of 180–220 or 100–120 mm Hg, respectively, as measured 
within primary health care. Except for high blood pressure, the same exclusion criteria 
were adopted as above, and this resulted in the exclusion of 24 patients. Of the eligible 
patients, 34 were excluded because of a lack of suffi cient uninterrupted sinus rhythm 
for the analysis of HRV. The fi nal analyses included thus data on 191 (82 women and 
109 men) hypertensive patients.
4.2 Heart rate and continuous arterial pressure signal acquisition
In populations 1 and 3, the recordings for the assessment of HRV, APV, and BRS were 
carried out between 8.30 a.m. and 12.00 a.m. in an isolated examination room at a 
stable temperature between 20 and 22 °C. The subjects were requested to avoid coffee, 
tea, cola drinks, and smoking for 12 hours, and alcoholic beverages for 24 hours before 
the investigations. A light breakfast was allowed not later than 2 hours before these 
investigations. The ECG was recorded after a 10-minute supine rest for 5 minutes 
while subjects were resting supine and breathing freely (I) or at a controlled frequency 
of 0.25 Hz (15 breaths per minute) (II–V). R-R intervals were measured from chest 
leads V1–V6 of the ECG. The signal was digitized and fed into a computer. 
In population 2, ECG was recorded for 45 minutes with an ambulatory ECG device 
(Dynacord Holter Recorder, Model 420, DM Scientifi c, Irvine, CA, USA) with a 
sampling frequency of 256 Hz. Each subject was monitored for 15 minutes in a supine 
posture, for 15 minutes in a sitting posture while breathing quietly at a frequency 
of 0.25 Hz, and for 15 minutes while walking. The duration of the recordings was 
chosen after a pilot study involving 37 normotensive and 40 hypertensive subjects by 
calculating the shortest period that would give a reasonable correlation (r = 0.6) with 
the 24-hour measures of HRV (225). The ECG recordings were performed between 
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7 a.m. and 3 p.m., and the data were transferred from the Del Mar Avionics scanner 
(Model 500, Del Mar Avionics, Irvine, CA, USA) to a computer for the analysis of 
HRV.
A photoplethysmographic technique (Finapres 2300, Ohmeda, Englewood, CO, USA) 
was applied to record the continuous arterial pressure signal. The reliability of this 
technique has been assessed (50). In population 1, a beat-to-beat arterial pressure 
tracking was obtained from the middle phalanx of the third fi nger of the left hand. In 
population 2, it was recorded from the second fi nger of the left hand. The fi nger with 
a carefully fi tted cuff was held at heart level. The automatic servo-adjustment option 
of the Finapres device was disabled during the recordings. Whereas the same time 
series were used in population 1 to assess all the measures of autonomic cardiovascular 
function, separate stationary segments without ectopic beats of about 5 minutes were 
used in population 2 to calculate beat-to-beat SAP variability and cross-spectral BRS. 
4.3 Heart rate variability
For a part of populations 1 and 3, subjects were excluded from the analyses if 
unstationarities, artifacts, or arrhythmias, even a single premature beat, made it 
impossible to obtain at least 4 minutes of continuous sequence. In population 2, 
premature beats and noise were excluded automatically and manually, and the gaps 
were refi lled with an average value computed from data of the local neighborhood. 
Segments with > 85% qualifi ed beats were included in the analysis. The time domain 
measures of HRV evaluated in this study were SDNN (I, III, IV) and RMSSD (I).
Before spectral analyses, for a part of populations 1 and 3, time series were detrended, 
linearly interpolated, resampled at 5 Hz, and subjected to a Partzen window. 
Correspondingly, in population 2, a linear detrend was applied to the R-R interval 
data in segments of 512 samples to make it more stationary. The power density 
spectra of HRV were computed using either a fast Fourier transform algorithm with a 
triangular smoothing (populations 1 and 3) or an autoregressive model (population 2). 
The frequency bands for the assessment of total, HF, LF, and VLF powers of HRV 
were < 0.4 Hz, 0.15– 0.4 Hz, 0.04– 0.15 Hz, and < 0.04 Hz, in respective order. The 
spectral measures of HRV were analyzed as absolute units (ms2), and the LF and HF 
components also as normalized units (nu, %; I, III). 
A custom-built version of the CPRS software (CardioPulmonary Research Software, 
Absolute Aliens Ltd, Turku, Finland), specifi cally intended for computation of the 
power spectra of beat-to-beat PP, was used to calculate all the measures of autonomic 
cardiovascular function in populations 1 and 3. In population 2, another custom-made 
program was used (Hearts, Heart Signal Co, Kempele, Finland). Measurements were 
performed in compliance with the standards of the Task Force (8).
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4.4 Beat-to-beat arterial pressure variability
In population 1, the same time series, frequency bands, and spectral methods as 
described above for the assessment of HRV were used to calculate the beat-to-beat APV 
of SAP (II–V), DAP (II, IV, V), and PP (IV). In population 2, a fast Fourier algorithm 
was applied to calculate the beat-to-beat SAP variability in frequency bands including 
total power, LF power (0.04– 0.06 Hz), medium frequency power (0.07– 0.14 Hz), and 
HF power (0.15– 0.40 Hz). In study IV, standard deviations (SD) of beat-to-beat SAP, 
DAP, and PP were calculated to describe the overall variability of each signal.
4.5 Barorefl ex sensitivity
BRS was determined by cross-spectral analysis between R-R and SAP variabilities 
provided that the coeffi cient of coherence was > 0.50, and that the phase angle was 
negative (Figure 4). The cross-spectral BRS was calculated either from the LF band 
(0.04– 0.15 Hz, population 1) or from the combination of medium frequency and HF 
bands (0.07– 0.40 Hz, population 2). Data of 7 and 17 subjects in populations 1 and 2, 
respectively, did not meet the coherence and phase criteria but were used to calculate 
the power spectra of HRV and APV.
4.6 Blood pressure 
In studies I, II, IV, and V, blood pressure and heart rate were estimated by a trained 
nurse and averaged of 4 duplicate measures (310). Blood pressure was recorded with 
the subject sitting. A mercury sphygmomanometer was used, and the measurements 
were always made between 8 and 10 a.m. according to the guidelines of the American 
Society of Hypertension (311).
Ambulatory blood pressure recording was used in study III with an auscultatory 
device (Accutracker II, Suntech Medical Instruments, Raleigh, NC, USA) in 
population 1 (312) and with Space-Labs 90207 oscillometric unit (SpaceLabs Inc., 
Redmond, WA, USA) in population 2. PP was defi ned in both populations as the 
mean difference of all corresponding ambulatory 24-hour systolic and diastolic blood 
pressure readings. However, in study IV, PP was calculated from the 4 duplicate blood 
pressure readings.
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4.7 Lifestyle variables
For body weight the subjects were weighed in light clothing without shoes at an 
accuracy of 0.1 kg, and height was measured at an accuracy of 1 cm. Information 
on smoking and alcohol consumption was obtained by questionnaires. Smoking was 
expressed on a dichotomized scale (smokers or non-smokers). The alcoholic drinks 
were converted into grams of absolute ethanol per week. Alcohol intake was analyzed 
as a continuous variable (I) or as a categorical variable (teetotalers, and tertiles of 
women and men consuming alcohol; III, V). Dietary salt intake was estimated by 
urinary 24-hour sodium excretion.
4.8 Psychological factors
Three self-report questionnaires (II) were used for the assessment of psychological 
factors: a shortened 37-item version (BSI-37) of the original 53-item Brief Symptom 
Inventory (313), the shortened version of the Spielberger State-Trait Anger Expression 
Inventory (STAXI) (314), and the Toronto Alexithymia Scale (TAS-26) (315). The 
total score of the BSI-37 divided by the number of items, known as the general severity 
index, was used as an indicator of psychological distress. Symptom dimensions for 
somatization, depression, anxiety, hostility, and phobicity were derived from the BSI-
37. The total score of the TAS-26 was used as an indicator of alexithymia.
The TAS-26 consists of four factors which describe diffi culty in identifying and 
distinguishing between feelings and bodily sensations (Factor 1), diffi culty in describing 
feelings (Factor 2), reduced daydreaming (Factor 3), and externally oriented thinking 
(Factor 4). The STAXI consists of 31 items which refl ect the intensity of feelings 
of anger (state anger), the disposition to experience anger (trait anger), behaviorally 
expressed anger (anger-out), suppressed anger (anger-in), and self-control of anger 
behavior (anger control).
4.9 Laboratory analyses
Laboratory tests were conducted after a 12-hour requested fasting. The serum samples 
were frozen and stored at –70 °C until assayed. Urinary 24-hour sodium (I, V) and 
potassium (V) were analyzed by emission fl ame photometry. The urinary collections 
were judged to be complete in over 90% of subjects (310). Radioimmunoassay was 
used for the determination of plasma renin activity (Phadebas Angiotensin I test, 
Pharmacia Diagnostics, Stockholm, Sweden) and plasma aldosterone (Aldosterone 
RIA, Abbott Laboratories, Chicago, IL, USA) (I). Enzymatic methods were used for 
the determinations of serum cholesterol, triglyceride, glucose (Merck Diagnostica, 
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Darmstadt, Germany), and HDL cholesterol (Boehringer Mannheim, Germany) (IV, V). 
HDL cholesterol was analyzed after magnesium-phosphotungstate precipitation of very-
low-density lipoprotein and LDL cholesterol. The LDL cholesterol content was estimated 
by the Friedewald formula. Serum insulin was determined by microparticle enzyme 
immunoassay (Abbott Laboratories, Dainabot, Tokyo, Japan) (IV, V). The HOMA formula 
was used to assess insulin resistance (316) (IV, V).
4.10 Exercise capacity
Exercise stress testing with a bicycle ergometer was used to assess maximal oxygen 
uptake (V). The staged protocol was started at 3 minutes of pedaling at a power output 
of 20 W for women and 30 W for men. Thereafter the work rate was increased by 
a uniform amount every 2 minutes, with increments ranging from 10 to 20 W for 
women and 15 to 30 W for men, depending on a patient’s expected performance. 
Maximal oxygen uptake was calculated with a linear regression method based on 
maximal work capacity.
4.11 Body fat composition
BMI was calculated as the body weight in kilograms divided by the square of the 
height in meters. The body fat composition was determined with an RJL impedance 
meter (model BIA-101A/S & Spectrum, RJL Systems, Mt. Clemens, MI, USA) (V). 
The BIA equation of Lukaski ((0.734 · (height)2 / resistance) + (0.116 · weight) + 
(0.096 · reactance) + (0.878 · sex (Female=0, Male=1)) – 4.03) was used to estimate 
the fatfree mass, and fat mass was calculated as weight minus fatfree mass (317).
4.12 Statistical analyses
Before statistical analyses, the variables with skewed distributions were transformed 
logarithmically. The summary statistics are given as mean (SD) or mean (s.e.) for 
indexes of HRV. Group differences were compared with a two-way analysis of 
variance (ANOVA) (I), the non-parametric Mann-Whitney test (I), unpaired t-tests 
(III–V), or, for categorical variables, the χ2-test. Associations between continuous 
variables were studied with Pearson’s correlation coeffi cients (I–IV), adjusted partial 
correlation coeffi cients (I, IV, V), and linear regression (III).
Multivariate stepwise linear regression analyses were used to evaluate the independent 
associations of dependent variables. The effects of age and gender were controlled 
in these analyses (II, III, V). In study II, heart rate, systolic, and diastolic blood 
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pressures were fi nally forced into the model to evaluate whether the associations 
between psychological factors and dependent variables result from their relations to 
heart rate or blood pressure. In study V, after the observation of a preferential role of 
blood pressure over other characteristics of insulin resistance, multivariate regression 
analyses were repeated without systolic and diastolic blood pressures to test whether 
their removal brings out another component of the metabolic syndrome. In study III, 
the regression analyses were carried out with standardized variables for comparability 
of the regression coeffi cients of different variables between the two populations. In 
study I, the adjusted means of HRV variables were fi nally calculated for hypertensive 
and normotensive women and men after adjustment for statistically signifi cant 
covariates.
Statistical analyses were performed with the SPSS software (SPSS Inc., Chicago, IL, 
USA). P-values, derived from 2-tailed tests, less than 0.05 were considered statistically 
signifi cant. 
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Table 3. Indexes of HRV between hypertensive and normotensive subjects 
 Men Women  
    
 Hypertensive Normotensive Hypertensive Normotensive p*
 (n = 109) (n = 49) (n = 82) (n = 56) 
Total power 
ms2 1562.6 (138.5) 2977.4 (364.1) 1374.0 (118.8) 2392.1 (263.3)  
ln(ms2) 7.00 (0.08) 7.67 (0.13) 6.92 (0.09) 7.49 (0.10) < 0.001 
VLF power 
ms2 832.6 (79.1) 1424.9 (254.9) 711.2 (67.4) 1094.7 (123.5)  
ln(ms2) 6.31 (0.09) 6.79 (0.14) 6.22 (0.10) 6.72 (0.10) < 0.001 
LF power 
ms2 488.8 (54.2) 1017.8 (130.7) 372.2 (39.5) 721.8 (105.1)  
ln(ms2) 5.79 (0.09) 6.52 (0.14) 5.52 (0.10) 6.13 (0.13) < 0.001 
nu 68.8 (1.4) 65.9 (2.3) 57.9 (1.8) 59.1 (2.4) < 0.657 
HF power 
ms2 221.8 (29.1) 509.6 (90.5) 272.4 (38.8) 541.2 (93.9)  
ln(ms2) 4.83 (0.10) 5.71 (0.16) 5.09 (0.12) 5.63 (0.16) < 0.001 
nu 28.8 (1.3) 32.1 (2.2) 39.1 (1.7) 37.6 (2.3) < 0.622 
LF/HF ratio 
% 327.6 (20.6) 304.7 (35.8) 199.5 (16.5) 226.6 (25.0)  
ln(%) 5.56 (0.07) 5.42 (0.11) 5.04 (0.08) 5.11 (0.11) < 0.696 
RMSSD
ms 22 (1) 35 (2) 23 (1) 33 (3)  
ln(ms) 2.94 (0.05) 3.42 (0.08) 3.01 (0.06) 3.35 (0.07) < 0.001 
SDNN
ms 37.9 (1.4) 55.7 (3.1) 36.2 (1.6) 49.3 (2.6)  
ln(ms) 3.56 (0.04) 3.93 (0.07) 3.51 (0.05) 3.83 (0.05) < 0.001 
HF, high frequency; HRV, heart rate variability; LF, low frequency; RMSSD, the square root of the mean of 
squared differences between adjacent normal R-R intervals; SDNN, the standard deviation of normal-to-
normal R-R intervals; VLF, very low frequency. 
Values are mean (s.e.). There were no two-way interactions between gender and group factor 
(1 = hypertension, 2 = normotension). Gender was not significant as a main-effect term except for LF power 
(p = 0.004), normalized LF power (p < 0.001), normalized HF power (p < 0.001), and LF/HF ratio (p < 0.001). 
*p indicates the significance level of group factor as a main-effect term in the ANOVA model. 
5 RESULTS
The examined variables and the characteristics of study populations are presented in 
Table 2. 
5.1 Heart rate variability and its determinants in newly diagnosed 
untreated systemic hypertension (I)
All measures of HRV were reduced in hypertensive subjects as compared to their 
normotensive controls (Table 3). However, there were no differences in the normalized 
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components of HRV and the LF/HF ratio. Age, heart rate, blood pressure, and BMI 
showed negative crude or adjusted correlations with the indexes of HRV. There were 
consistent inverse relationships between PRA and the HF component of HRV and 
RMSSD (Figure 6; I, Table 3), and between PRA and SDNN (I, Table 3).
In multivariate regression analyses (Table 4), except for the LF component, absolute 
measures of HRV were independently associated with heart rate, age, and mean arterial 
pressure. The LF component was also explained by gender, women having lower 
LF powers than men. Decreased RMSSD and the HF component of HRV were also 
predicted by a high PRA. Even after adjustment for the independent predictors (age, 
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heart rate, and PRA), total (p = 0.007), VLF (p = 0.015), and LF (p = 0.011) powers in 
hypertensive women, and LF (p = 0.028) and HF (p = 0.006) powers in hypertensive 
men were lower when compared with their normotensive counterparts (I, Figure 2).
5.2 Psychological factors and autonomic cardiovascular 
regulation (II)
Psychological measures were strongly interrelated (Table 5). Only increased 
behaviorally expressed anger (anger-out) correlated with increased LF power of 
HRV (r = 0.18, p = 0.032). According to multivariate regression analyses, none of the 
psychological factors predicted HRV.
Higher scores of somatization, depression, anxiety, hostility, phobicity, and the general 
severity index of the BSI-37, and state anger of the STAXI were associated with 
higher LF power of APV (range of Pearson’s r from 0.16 to 0.31, Table 6) Multivariate 
regression analyses showed that increased anxiety was associated with increased LF 
power of SAP variability (standardized regression coeffi cient, β = 0.26, p = 0.001) and 
increased hostility with increased LF power of DAP variability (β = 0.30, p < 0.001), 
independently of age, gender, and other psychological factors. Most importantly, these 
associations remained essentially unchanged when heart rate, systolic, and diastolic 
blood pressures were added to the model (Table 7).
A higher score of somatization (r = 0.23) and a lower score of anger-in (r = – 0.16) 
were associated with increased HF power of SAP variability. Multivariate analysis 
showed that reduced anger-in (β = – 0.19, p = 0.020) and increased hostility (β = 0.18, 
p = 0.033) were associated with increased HF power of SAP variability independently 
of age, gender, other psychological factors, heart rate, systolic, and diastolic blood 
pressures (model R2 = 0.13, p = 0.005). None of the psychological variables were 
associated with the HF power of DAP variability.
Higher scores of somatization, depression, anxiety, hostility, phobicity, and the general 
severity index of the BSI-37 were associated with reduced BRS (range of Pearson’s r 
from – 0.19 to – 0.29, Table 6). Multivariate regression analysis showed that higher age 
(β = – 0.39, p < 0.001), higher anxiety  (β = – 0.29, p < 0.001), and a lower total score 
of the TAS-26 (β = 0.16, p = 0.050) were associated with reduced BRS independently 
of age, gender, and other psychological factors (model R2 = 0.25, p < 0.001). The 
association between a higher score of anxiety and lower BRS remained unchanged, 
but the association between the total score of the TAS-26 and BRS disappeared after 
heart rate, systolic, and diastolic blood pressures were added to the model (Table 7).
49
T
ab
le
 5
. 
Co
rr
el
at
io
n 
m
at
rix
 o
f s
el
ec
te
d 
ps
yc
ho
lo
gi
ca
l m
ea
su
re
s 
 
D
ep
re
ss
io
n 
A
nx
ie
ty
 
H
os
til
ity
 
Ph
ob
ic
ity
 
G
en
er
al
 
To
ta
l 
St
at
e 
an
ge
r 
A
ng
er
-o
ut
 
A
ng
er
-in
 
 
 
 
 
 
se
ve
rit
y 
in
de
x 
TA
S-
26
 
So
m
at
iz
at
io
n 
0.
47
**
* 
0.
60
**
* 
0.
43
**
* 
0.
48
**
* 
0.
76
**
* 
0.
30
**
* 
0.
32
**
* 
0.
05
 
0.
11
 
D
ep
re
ss
io
n 
—
 
0.
66
**
* 
0.
55
**
* 
0.
52
**
* 
0.
83
**
* 
0.
29
**
* 
0.
26
**
 
0.
22
**
 
0.
31
**
* 
A
nx
ie
ty
 
 
—
 
0.
63
**
* 
0.
68
**
* 
0.
87
**
* 
0.
32
**
* 
0.
45
**
* 
0.
24
**
 
0.
18
* 
H
os
til
ity
 
 
 
—
 
0.
41
**
* 
0.
74
**
* 
0.
13
 
0.
29
**
* 
0.
41
**
* 
0.
13
 
Ph
ob
ic
ity
 
 
 
 
—
 
0.
69
**
* 
0.
37
**
* 
0.
32
**
* 
0.
14
 
0.
12
 
G
en
er
al
 se
ve
rit
y 
in
de
x 
 
 
 
—
 
0.
38
**
* 
0.
41
**
* 
0.
22
**
 
0.
26
**
 
To
ta
l T
A
S-
26
 
 
 
 
 
 
—
 
0.
11
 
–0
.1
6 
0.
29
**
* 
St
at
e 
an
ge
r 
 
 
 
 
 
 
—
 
0.
11
 
0.
25
**
 
A
ng
er
-o
ut
 
 
 
 
 
 
 
 
—
 
–0
.1
4 
TA
S-
26
, T
or
on
to
 A
le
xi
th
ym
ia
 S
ca
le
. *
p 
< 
0.
05
, *
*p
 <
 0
.0
1,
 *
**
p 
< 
0.
00
1.
  
T
ab
le
 6
. 
Pe
ar
so
n’
s c
or
re
la
tio
n 
co
ef
fic
ie
nt
s b
et
we
en
 se
le
ct
ed
 p
sy
ch
ol
og
ic
al
 m
ea
su
re
s a
nd
 th
e 
in
de
xe
s o
f b
ea
t-t
o-
be
at
 A
PV
 a
nd
 B
RS
 
 
LF
 p
ow
er
 o
f S
A
P 
H
F 
po
w
er
 o
f S
A
P 
LF
 p
ow
er
 o
f D
A
P 
H
F 
po
w
er
 o
f D
A
P 
B
R
Sa
 
va
ria
bi
lit
y 
va
ria
bi
lit
y 
va
ria
bi
lit
y 
va
ria
bi
lit
y 
 
 
ln
(m
m
 H
g)
2  
ln
(m
m
 H
g)
2  
ln
(m
m
 H
g)
2  
ln
(m
m
 H
g)
2
ln
(m
s/
m
m
 H
g)
 
So
m
at
iz
at
io
n 
0.
19
* 
0.
20
* 
0.
16
* 
0.
12
 
–0
.2
1*
 
D
ep
re
ss
io
n 
0.
19
* 
0.
11
 
0.
17
* 
0.
09
 
–0
.2
1*
 
A
nx
ie
ty
 
0.
26
**
 
0.
08
 
0.
29
**
* 
0.
03
 
–0
.2
9*
**
 
H
os
til
ity
 
0.
22
**
 
0.
16
 
0.
31
**
* 
0.
15
 
–0
.1
9*
 
Ph
ob
ic
ity
 
0.
15
 
0.
02
 
0.
16
* 
–0
.0
1 
–0
.2
2*
* 
G
en
er
al
 se
ve
rit
y 
in
de
x 
0.
23
**
 
0.
13
 
0.
24
**
 
0.
09
 
–0
.2
7*
* 
To
ta
l T
A
S-
26
 
0.
04
 
–0
.1
1 
0.
00
 
0.
06
 
0.
03
 
St
at
e 
an
ge
r 
0.
12
 
–0
.0
2 
0.
16
* 
–0
.0
4 
–0
.0
7 
A
ng
er
-in
 
0.
06
 
–0
.1
6*
 
0.
07
 
0.
05
 
–0
.0
9 
A
PV
, a
rte
ria
l 
pr
es
su
re
 v
ar
ia
bi
lit
y;
 B
R
S,
 b
ar
or
ef
le
x 
se
ns
iti
vi
ty
; 
D
A
P,
 d
ia
st
ol
ic
 a
rte
ria
l 
pr
es
su
re
; 
H
F,
 h
ig
h 
fr
eq
ue
nc
y;
 L
F,
 l
ow
 f
re
qu
en
cy
; 
SA
P,
 s
ys
to
lic
 a
rte
ria
l 
pr
es
su
re
; T
A
S-
26
, T
or
on
to
 A
le
xi
th
ym
ia
 S
ca
le
. *
p 
< 
0.
05
, *
*p
 <
 0
.0
1,
 *
**
p 
< 
0.
00
1.
 a n
 =
 1
43
, o
th
er
w
is
e 
n 
= 
15
0.
 
50
Table 7. Final multivariate regression models testing independent associations of 
psychological measures with the LF components of SAP and DAP variabilities and BRS 
 LF power of SAP LF power of DAP BRSa
 variability variability  
 ln(mm Hg2) ln(mm Hg2) ln(ms/mm Hg) 
Age (yr) 0.13 (0.106) –0.08 (0.364) –0.36 (<0.001) 
Gender (1 = men; 2 = women) –0.02 (0.797) 0.05 (0.595) –0.09 (0.233) 
Anxiety 0.25 (0.002) — –0.27 (0.001) 
Hostility — 0.29 (0.001) — 
Heart rate (beats/min) 0.03 (0.699) 0.02 (0.836) –0.18 (0.031) 
Systolic blood pressure (mm Hg) 0.23 (0.088) 0.09 (0.626) –0.05 (0.655) 
Diastolic blood pressure (mm Hg) –0.01 (0.963) 0.05 (0.381) –0.14 (0.250) 
Model R2 0.16 0.11 0.34 
Model p <0.001 0.010 <0.001 
Variable values are ? (p). ?, regression coefficient corresponding standardized variable; p, significance of the 
variable in the model; R2, R square. BRS, baroreflex sensitivity; DAP, diastolic arterial pressure; HF, high 
frequency; LF, low frequency; SAP, systolic arterial pressure. 
an = 143, otherwise n = 150. 
5.3 Ambulatory pulse pressure and autonomic cardiovascular 
regulation (III)
Associations between 24-hour ambulatory PP and autonomic cardiovascular regulation 
were studied in two separate populations. PP correlated inversely with the HF power 
of HRV in population 1 (r =  – 0.18, p = 0.025), and with the LF power of HRV in 
population 2 (r = – 0.14, p = 0.039). However, correlations between PP and HRV 
were not signifi cant after controlling for age and gender.
In both populations, PP correlated inversely with BRS (r = – 0.33, p < 0.001, 
population 1; r = – 0.29, p < 0.001, population 2), and according to multivariate 
regression analyses, independently of age and gender (β = – 0.28, p < 0.001, 
population 1; β = – 0.22, p = 0.003, population 2). By multivariate analyses with 
age, gender, 24-hour ambulatory diastolic blood pressure, BMI, alcohol intake, and 
smoking increased 24-hour ambulatory PP was still an independent determinant of 
decreased BRS (Table 8).
Elevated PP was related to increased beat-to-beat SAP variability. By multivariate 
analyses, higher 24-hour ambulatory PP was associated in population 1 with higher 
total, VLF, LF (β = 0.40, 0.37, 0.31, respectively, p < 0.001 for all), and HF (β = 0.28, 
p = 0.001) powers of SAP variability, and in population 2, with higher total, LF, and 
medium frequency powers of SAP variability (β = 0.16, 0.15 and 0.16, respectively, 
p < 0.05 for all).
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Table 8. Ambulatory pulse pressure as a determinant of BRS 
 Population 1 Population 2 
   
? CI p ? CI p
Age (yr) –0.28 –0.43 to –0.13 <0.001 –0.23 –0.38 to –0.09 0.002 
Gender (female vs male) –0.25 –0.43 to –0.08 0.005 0.03 –0.13 to +0.18 0.746 
Body mass index (kg/m2) –0.20 –0.36 to –0.04 0.015   —   
24-h pulse pressure (mm Hg) –0.20 –0.37 to –0.04 0.018 –0.16 –0.30 to –0.01 0.033 
24-h diastolic blood pressure (mm Hg)   —   –0.23 –0.37 to –0.09 0.002 
Population 1: Model p < 0.001, R2 = 0.27, n = 149 
Population 2: Model p < 0.001, R2 = 0.16, n = 214 
BRS, baroreflex sensitivity. ?, regression coefficient corresponding standardized variable (except gender); CI,
95% confidence interval for the regression coefficient; p, significance of the variable in the model; R2,
R square. Dependent variable in the analysis was natural logarithmic corrected BRS. Age and gender were 
forced in the model. Ambulatory diastolic and pulse pressures, body mass index, alcohol intake, and smoking 
were tested in a stepwise manner. 
5.4 Power spectral analysis of beat-to-beat pulse pressure 
variability (IV)
Like the power spectra of beat-to-beat R-R interval, SAP, and DAP variabilities, 
the power spectrum of beat-to-beat PP variability showed a large interindividual 
variation, a skewed distribution, and similar frequency peaks (IV, Table 2; Figure 7). 
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An unexpected fi nding was that the proportion of HF to total power was higher in PP 
than in SAP and DAP variabilities (Figure 8).
Table 9. Correlation coefficients of beat-to-beat PP variability with the measures of 
SAP, DAP, and R-R interval variabilities and BRS 
 LF power of PP HF power of PP SD of beat-to-beat  
 variability variability PP 
 ln(mm Hg2) ln(mm Hg2) ln(mm Hg) 
SBP variability 
LF power, ln(mm Hg2) 0.89*** 0.13 0.61*** 
HF power, ln(mm Hg2) 0.22** 0.86*** 0.24** 
SD, ln(mm Hg) 0.74*** 0.17* 0.92*** 
DBP variability 
LF power, ln(mm Hg2) 0.55*** 0.08 0.24** 
HF power, ln(mm Hg2) 0.16* 0.33*** 0.16 
SD, ln(mm Hg) 0.44*** 0.19* 0.46*** 
RR interval variability 
LF power, ln(ms2) 0.13 0.09 0.03 
HF power, ln(ms2) –0.13 0.30*** –0.07 
SD, ln(ms) –0.09 0.18* –0.06 
BRS, ln(ms/mm Hg)a –0.48*** –0.07 –0.32*** 
BRS, baroreflex sensitivity; DAP, diastolic arterial pressure; HF, high frequency; LF, low frequency; PP, pulse 
pressure; SAP, systolic arterial pressure; SD, standard deviation. 
*p < 0.05, **p < 0.01, ***p < 0.001. 
an = 143, otherwise n = 150. 
The SD of beat-to-beat PP correlated closely with the LF component of PP variability 
(r = 0.76, p < 0.001), but only weakly with the HF component of PP variability 
(r = 0.18, p < 0.032). There was no signifi cant correlation between the HF and LF 
components of PP variability. Measures of PP variability were closely related to the 
respective measures of SAP variability and less closely to those of DAP variability 
(Table 9). A higher HF component of PP variability was associated with a higher HF 
component of HRV, but the LF component of PP variability did not correlate with the 
respective component of HRV.
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Table 10. Age- and gender-adjusted correlation coefficients between the indexes of beat-
to-beat PP variability and cardiovascular risk factors 
 LF power of PP HF power of PP SD of beat-to-beat  
 variability variability PP 
 ln(mm Hg2) ln(mm Hg2) ln(mm Hg) 
Systolic blood pressure (mm Hg) 0.28** 0.14 0.24** 
Diastolic blood pressure (mm Hg) 0.15 –0.04 0.05 
Pulse pressure (mm Hg) 0.27** 0.26** 0.31*** 
Heart rate (beats/min) 0.10 –0.06 0.06 
Body mass index (kg/m2) 0.22** 0.05 0.22** 
Cholesterol (mmol/l) 0.03 0.09 –0.03 
HDL-Cholesterol (mmol/l) –0.14 –0.11 –0.08 
Triglycerides ln(mmol/l) 0.16* 0.10 0.07 
LDL-Cholesterol (mmol/l) 0.03 0.08 –0.03 
Glucose (mmol/l) 0.11 –0.10 0.09 
Insulin ln(mU/l) 0.17* 0.15 0.11 
HOMA ln(mmol·mU/l2) 0.18* 0.14 0.12 
HOMA, homeostasis model assessment. *p < 0.05, **p < 0.01, ***p < 0.001. 
5.5 Determinants of beat-to-beat pulse pressure variability (IV)
The SD of beat-to-beat PP (r = 0.21, p = 0.010) and the LF component (r = 0.17, 
p = 0.041) of PP variability increased with age. SD was greater in men than in 
women (mean ± s.e. 4.4 ± 0.2 vs. 3.9 ± 0.2, p = 0.045), but for the spectral powers, no 
signifi cant gender differences were found.
Age- and gender-adjusted correlations (Table 10) showed that the SD of beat-to-beat 
PP and the LF component of PP variability increased with PP, systolic blood pressure, 
and BMI. A higher LF component of PP variability was also associated with higher 
levels of serum insulin, HOMA, and triglycerides. The HF component of PP variability 
correlated only with PP.
Multivariate stepwise regression analysis showed that elevated PP (β = 0.24, 
p = 0.003) and higher BMI (β = 0.19, p = 0.020) were associated with an increased 
LF component of beat-to-beat PP variability independently of age, gender, insulin 
resistance, serum triglycerides, and smoking (Model R2 = 0.15, p < 0.001). 
5.6 Association of beat-to-beat pulse pressure variability with 
barorefl ex sensitivity (IV)
Cross-spectral BRS correlated inversely with the LF component of PP variability (r = 
– 0.48, p < 0.001) and with the SD of beat-to-beat PP (r = – 0.32, p < 0.001). To test 
an independent role of short-term PP fl uctuation as a determinant of BRS, multivariate 
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models were made with static blood pressure readings, age, and gender as explanatory 
variables. Age, gender, and systolic blood pressure alone turned out to explain 24.5%, 
and together with the LF component of PP variability 41.0%, of the variation in BRS. 
Age, gender, and diastolic blood pressure explained 25.7% of the variation in BRS, 
whereas the predictive value of these variables combined with the LF component of 
PP variability was 43.7%.
5.7 Effects of insulin resistance and exercise capacity on autonomic 
cardiovascular regulation (V)
Factors pertinent to the metabolic syndrome, e.g. elevated levels of blood pressure, 
serum triglycerides, insulin, insulin resistance, BMI, and body fat mass were inversely 
associated with the LF and HF components of HRV and with BRS (Table 11). The 
same factors correlated positively with the HF components of beat-to-beat SAP and 
DAP variabilities, but, except for blood pressure, not with their LF components. 
The maximal oxygen uptake index was positively associated with the LF and HF 
components of HRV and with BRS, and negatively with the HF components of beat-
to-beat SAP and DAP variabilities. Smoking, alcohol consumption, and urinary 
sodium and potassium excretion were not signifi cantly associated with HRV, beat-to-
beat APV, or BRS.
Multivariate regression analyses showed that higher age (β = – 0.31, p < 0.001) and 
higher diastolic blood pressure (β = – 0.29, p < 0.001) were independent determinants 
of a reduced HF component of HRV (model R2 = 0.22, p < 0.001). Higher age (β = 
– 0.28, p = 0.001) and a lower maximal oxygen uptake index (β = 0.25, p = 0.011) 
were independent correlates of decreased LF component of HRV (model R2 = 0.21, 
p < 0.001). Correspondingly, a lower level of maximal oxygen uptake index was 
associated with increased HF components of beat-to-beat SAP (β = – 0.46, p < 0.001) 
and DAP (β =  – 0.30, p = 0.006) variabilities. Higher age (β = – 0.33, p < 0.001), 
higher diastolic blood pressure (β = – 0.22, p = 0.007), and a higher proportion of fat 
of the total body weight (β = – 0.19, p = 0.030) were associated with reduced BRS 
(model R2 = 0.28, p < 0.001). There was a reasonable correlation between diastolic 
blood pressure and HOMA (r = 0.47, p < 0.001), and between diastolic blood pressure 
and the serum triglyceride concentration (r = 0.49, p < 0.001). Multivariate regression 
analyses without blood pressure showed that increased HOMA was a determinant of 
reduced HF component of HRV (β = – 0.19, p = 0.021), and a higher level of serum 
triglycerides (β = – 0.22, p = 0.007) was as a determinant of reduced BRS.
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6 DISCUSSION
6.1 Heart rate variability in essential hypertension (I)
Divergent results from studies examining HRV in essential hypertension can be 
ascribed to a number of factors. Whereas differences in measurement conditions 
and inconsistency in the expression of the indexes of HRV may explain some of the 
differing fi ndings, methodological differences regarding the computation of the HRV 
measures play a minor role (218). Differences between the examined populations 
account, perhaps, for a large part of the divergence in results. Studies differ in respect 
to the selection criteria of hypertensive subjects and have handled various confounding 
factors, e.g. medication and co-morbidities, differently. Although studies with treated 
hypertensive individuals mainly support the fi nding of decreased HRV (225, 318), 
there are data suggesting that long-term antihypertensive treatment might in part 
correct abnormalities of HRV (205). Studies reporting HRV separately for untreated 
and treated hypertensive subjects (203, 218) indicate that the latter ones, in general, 
have more severely reduced HRV. Only few studies have used a population-based 
design (204, 218, 225).
Even after careful exclusion of medications and illnesses affecting autonomic 
cardiovascular function, factors remain that are inherent to hypertension; such factors 
may contribute to the divergent results. These include insulin sensitivity (263), a 
clustering of hypertension with other components of the metabolic syndrome (264, 
269), sodium sensitivity (319–321), left ventricular hypertrophy (222, 322, 323), and 
presence or absence of a nocturnal fall in blood pressure (324, 325). High sodium 
intake enhances HRV and APV in hypertensive and in normotensive subjects (319). 
Sodium sensitivity is inversely related to BRS and HRV in hypertensive subjects (321), 
and sodium sensitive hypertensive subjects have a blunted capability to increase BRS 
or the HF component of HRV in response to a high sodium intake (319, 320). Among 
hypertensive patients with left ventricular hypertrophy, the circadian variation in HRV 
is blunted (326) and HRV is decreased both in comparison to normotensive subjects 
(222, 322, 323, 326) and hypertensive patients without left ventricular hypertrophy 
(222). Left ventricular mass is inversely correlated to the LF (222, 322, 323) and HF 
(322, 323) components of HRV. The absence of a nocturnal fall in blood pressure, 
i.e. non-dipping phenomenon, is related to decreased HRV (324, 325), to blunted 
circadian variation in HRV (325), and to an abnormal response of HRV to change of 
posture (324). Studies on the white-coat effect have resulted in confl icting fi ndings 
(327, 328).
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After careful exclusion of subjects with confounding factors, the present study (I) 
compared the indexes of HRV in newly diagnosed, untreated middle-aged hypertensive 
men and women with healthy counterparts of the general population. The observation 
that decreased SDNN, RMSSD, and all absolute frequency domain measures of HRV 
differentiated untreated hypertensive subjects as a group separate of their normotensive 
control group is in line with fi ndings in previous population-based (204, 218, 225) and 
other studies (203, 234). Compared with the present study, the hypertensive subjects 
in these studies were older (203, 204, 218, 225, 234), exclusively male (225), or a 
subgroup (203, 218), or all (225, 234) had received (234), or were receiving (203, 
218, 225) antihypertensive treatment. Only one of these studies (218) reported an 
increase in the LF/HF ratio of HRV in untreated hypertensive subjects. However, this 
increase was secondary to a reduction in the absolute HF component of HRV, and the 
LF component of HRV in arbitrary units was not increased. Thus, these studies and the 
present one did not support the concept of increased sympathetic activity in essential 
hypertension, but did consistently show attenuation of vagal modulation of HRV.
Study I shows that higher age, heart rate, and blood pressure were independent 
determinants of decreased measures of HRV in the combined sample of hypertensive 
subjects and healthy controls. A new fi nding was that the association of blood pressure 
with HRV is independent of heart rate. In accordance with previous studies involving 
hypertensive subjects (234, 318), higher age was associated with reduced HRV. Study 
I also confi rmed the previous fi ndings that female gender is related to an increase in 
normalized HF component and to decreases in arbitrary or normalized LF components 
and LF/HF ratio of HRV (234). The most interesting fi nding of the study was that 
increased plasma renin activity was an independent determinant of decreased vagal 
modulation of heart rate, as indicated by RMSSD and the HF component of HRV. 
Although no obvious explanation presents itself for this fi nding, it might be related to 
sodium sensitivity (321).
6.2 Determinants of heart rate variability in healthy subjects (II, 
III, V)
Age, gender, heart rate, and blood pressure affect HRV in an important way. The 
present studies were not primarily focused on these variables, but attempted rather 
to control the effects of age and gender (II, III, and V), and of heart rate and blood 
pressure (II) by running multivariate regression analyses of the data. Although reported 
only in the study V, advanced age was related to decreased HRV in all studies. Gender 
differences were also identifi ed particularly in the normalized components of HRV. In 
study V, higher diastolic blood pressure was an independent determinant of reduced 
HF component of HRV in multivariate regression analysis that tested several factors 
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related to insulin resistance. Although study III revealed an association between PP and 
BRS, PP was not independently associated with any measure of HRV. This suggests 
that PP does not have any signifi cant effect on tonic autonomic cardiovascular control 
and that it affects barorefl ex-mediated heart rate fl uctuations.
Research on the relationship between psychological factors and autonomic 
cardiovascular regulation has yielded inconsistent fi ndings, and the majority of 
data originates from small case-control studies. Although many studies have linked 
depression with autonomic cardiovascular regulation in coronary heart disease (158–
163), depression might be associated with the severity of coronary heart disease, 
which, in turn, could affect HRV – an association that is often overlooked. Only 
seldom is there comprehensive information on left ventricular systolic function or 
severity of coronary heart disease, based on angiographic, stress echocardiographic, 
or scintigraphic evaluation (158–162). Two studies that controlled carefully for the 
severity of coronary heart disease yielded negative results (329, 330).
Study II was the fi rst to report the effects of psychological factors on HRV, APV, and 
BRS in a general population. The fi ndings suggest that the LF and HF components of 
short-term HRV under supine resting conditions do not refl ect symptoms of anxiety, 
hostility, and depression in middle-aged healthy men and women. These negative 
fi ndings may be explained by the population-based setup and the strict exclusion of 
medicated patients with psychiatric disorders. The effects of psychological factors 
on HRV may only be identifi ed in recordings that are suffi ciently long to produce 
transactions between individuals and their environments (171). Posture may also 
modify results, as persons with panic disorder or anxiety have been found to have 
altered HRV only when standing, not supine (67, 139, 141, 150). These fi ndings might 
indicate lower sympathetic reserve, because there are no differences in BRS between 
panic disorder patients and healthy subjects at rest (147). Thus, prudence is necessary 
when drawing conclusions from the present fi ndings.
The fi ndings in study V are in harmony with previous studies showing that a 
disturbance in glucose metabolism, measured by fasting glucose, insulin, or 
glycosylated hemoglobin (117, 249, 250), higher levels of triglycerides (104, 113, 
117, 123), blood pressure (235, 269), and BMI (104, 117, 235) are associated, alone 
or in combination (269, 270), with a reduction of HRV. Previous studies have included 
diabetics and subjects treated for hypertension or other cardiovascular diseases (117, 
235, 250, 269). The observations in study show that the characteristics of the metabolic 
syndrome relate to reduced LF and HF components of HRV also in a middle-aged 
healthy general population. In accordance with previous studies (12), higher HF and 
LF components of HRV were associated with an increment in maximal oxygen uptake 
index suggesting that a high level of physical fi tness has a counteractive effect on 
HRV (V).
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6.3 Determinants of beat-to-beat arterial pressure variability in 
healthy subjects (II, III, V)
Beat-to-beat APV has been the subject of only little research. One obvious reason 
for this is that this measure lacks prognostic implications. Although there are no 
longitudinal studies on beat-to-beat APV, the ambulatory blood pressure variability 
has been shown to carry prognostic information (331).
In the present study (II), a higher score of state anger and higher symptom scores of 
depression, somatization, anxiety, hostility, and phobicity were related to increased 
LF power of APV. Anxiety and hostility were the strongest determinants of increased 
LF powers of SAP and DAP variabilities. Interestingly, they explained beat-to-beat 
APV over age, gender, heart rate, and blood pressure, which are the main predictors 
of most measures of autonomic function. The second important fi nding was that 
the multivariate models used explained only a small fraction of the variation in the 
LF component of APV. Thus, the vast majority of the short-term beat-to-beat APV 
is explained by factors not evaluated in study II. Psychological factors were not 
associated with the HF component of DAP variability, and the associations between 
the HF component of SAP variability and anger-in or hostility were only weak. This 
absence of relation is logical because the HF component of APV refl ects principally 
respiratory mechanics (332).
In two separate population-based samples of middle-aged women and men (III) 
increased 24-hour ambulatory PP was associated with increased beat-to-beat SAP 
variability independent of age, gender, diastolic blood pressure, BMI, smoking, 
and alcohol intake. Arterial stiffening might increase beat-to-beat APV through its 
effects on pulse wave refl ection. On the other hand, arterial stiffening may impair the 
buffering function of the baroreceptor refl ex, which may lead into increased APV. 
Consistent with the conclusion that arterial stiffening may, in part, explain increased 
oscillations in SAP, a recent study in newly diagnosed untreated hypertensive patients 
found that higher ambulatory blood pressure variability was a predictor of increased 
PWV (333).
An increase in the LF power of SAP variability has been reported in subjects with 
insulin dependent diabetes (253). Study V could not demonstrate signifi cant relations 
between the characteristics of insulin resistance and LF components of SAP or DAP 
variabilities. On the other hand, higher HF components of SAP and DAP variabilities 
were consistently associated with higher levels of serum insulin, triglycerides, HOMA, 
BMI, and body fat content, and with a lower level of HDL cholesterol. Another new 
fi nding was that a higher level of physical fi tness is associated with decreased HF 
components of beat-to-beat SAP and DAP variabilities. Because the HF component of 
beat-to-beat APV results principally from rhythmic changes of intrathoracic pressure 
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owing to respiratory mechanics (332), these fi ndings may merely refl ect indirect 
effects of physical fi tness.
6.4 Determinants of barorefl ex sensitivity in healthy
subjects (II–V)
Across many studies, the main predictors of BRS are age (91, 92, 99–101), gender 
(91, 92, 105), blood pressure level (91, 92), and heart rate (91, 92). The effects of age 
and gender were controlled for in studies II, III, and V, and also the effects of heart 
rate and blood pressure in study II when the multivariate regression analyses were run. 
Consistent with previous studies, increased age was the most important determinant 
of reduced BRS by multivariate regression (II, III and V). Gender remained an 
independent determinant of BRS only for the part of population 1 in study III. The 
lack of an association in population 2 was not unexpected, because, in contrast to 
uniformly observed infl uence of age, gender has not been found to have an effect 
on BRS in every study. On the other hand, the lack of an independent association in 
studies II and V of population 1 suggests that gender effects are partly intermixed 
with the other studied variables, e.g. psychological factors, characteristics of insulin 
resistance, and physical fi tness. 
Study II and previous studies (153, 166) suggest that, when using short-term 
measurements from recumbent subjects, BRS refl ects more sensitively than HRV the 
effects of psychological factors on autonomic cardiovascular function. Depression, 
increased anxiety, hostility, phobicity, and the general severity index of the BSI-37 were 
related to a reduction in BRS. Anxiety was the strongest psychological determinant of 
decreased BRS, independently of age, gender, other psychological factors, heart rate, 
and blood pressure. 
Study III involved two separate, apparently healthy population-based samples of 
middle-aged women and men. Here, increased ambulatory PP was associated with a 
decreased BRS independent of age, gender, diastolic blood pressure, BMI, alcohol 
intake, and smoking. Although enhanced sympathetic drive may result in simultaneous 
attenuation of BRS and increased PP, it is more likely that a common denominator, 
e.g. increased arterial stiffness, accounts for these changes. Stiffness of the aorta might 
reduce the stretch of baroreceptors in response to a rise in arterial pressure. Concurrent 
with this idea, BRS has been correlated inversely with the measures of arterial stiffness 
in patients with recent stroke or chronic hemodialysis (308, 309). Carotid artery 
distensibility has been related to BRS even in healthy young people (334).
A recent population-based study found that BRS correlated negatively with waist 
circumference, BMI, insulin, HOMA, glycosylated hemoglobin, fasting glucose, 
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triglycerides, total and LDL cholesterol, and systolic blood pressure (335). Concordant 
with this and previous studies (100, 235), study V showed that BRS correlates inversely 
with BMI, insulin, HOMA, triglycerides, systolic, and diastolic blood pressures. 
There was a negative association with fat mass and with the proportion of body fat. 
Although a low level of HDL cholesterol is one of the characteristic features of the 
metabolic syndrome, a recent study did not fi nd a signifi cant association between 
BRS and HDL cholesterol (335). In contrast to that study, and in accordance with 
clinical expectations and a previous study (234), study V showed a positive univariate 
association between BRS and HDL cholesterol.
In study V, the maximal oxygen uptake index showed a positive univariate association 
with BRS, implicating that good physical fi tness has a protecting effect on barorefl ex 
function. This fi nding is in line with previous studies showing a correlation between 
BRS and exercise capacity in healthy subjects (91, 118) and an increase in BRS after 
exercise training (121).
Multivariate regression analysis (V) showed that higher age, higher diastolic blood 
pressure, and a higher body fat percentage were independent determinants of 
decreased BRS. An important role of blood pressure among the factors associated 
with insulin resistance is in accordance with a recent fi nding that blood pressure had 
a predominant effect over other components of metabolic syndrome on the arterial 
intima-media thickness and PWV (336). On the other hand, a recent population-based 
study that evaluated many factors associated with insulin resistance, showed that the 
only multivariate predictors of BRS were age and waist circumference (335).
An interesting fi nding in study IV was that increased LF component of beat-to-beat 
PP variability was an approximately twice as powerful determinant of decreased 
BRS as systolic and diastolic blood pressures alone and together, and was able to 
totally replace them as a determinant of BRS. This fi nding may indicate that short-
term fl uctuation of PP, rather than a static blood pressure level, modulates BRS. 
Alternatively, impaired barorefl ex function may lead to increased fl uctuation in PP. It 
is also possible that an increase in beat-to-beat PP variability and a decrease in BRS 
may parallel a common denominator such as vascular stiffening. The present study 
did not clarify the mechanisms behind these associations.
6.5 Beat-to-beat pulse pressure variability in healthy subjects (IV)
The novel hypothesis was that arterial stiffening leads to increased beat-to-beat 
variability of PP. Using custom-built software, specifi cally intended for computation 
of beat-to-beat time series and power spectra of PP, the present study showed that 
the frequency distribution in the power spectral density of beat-to-beat PP bears 
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remarkable similarity to those in R-R interval, SAP, and DAP variabilities. A fi nding 
of a prominent respiratory peak in PP variability is in accordance with similar fi ndings 
in rats (337). Thus, although PP variability closely correlates with SAP variability, the 
HF component of PP variability resembles more that of HRV. However, in contrast 
to the respective component of HRV (V), the HF power of PP variability (IV) did 
not correlate with BMI, serum insulin, HOMA, or serum triglycerides. The absence 
of these associations might suggest that non-autonomic mechanisms are principally 
responsible for respiratory oscillations of PP in recumbent humans.
There was an association between increased beat-to-beat PP variability and elevated PP 
in a middle-aged general population (IV). The initial hypothesis was also supported by 
the observed associations between beat-to-beat PP variability and clinical risk factors 
of arterial stiffening. The increased LF component of beat-to-beat PP variability was 
associated with advancing age and factors pertinent to insulin resistance including 
higher BMI, higher levels of serum insulin, HOMA, and triglycerides. The absence of 
a relation between PP variability and serum cholesterol concentration is in accordance 
with studies showing a lack of or even a negative association between serum cholesterol 
and aortic stiffness (338, 339).
6.6 Limitations
Although consistent with the Task Force (8), the short-term recordings of beat-to-beat 
oscillations in R-R interval and arterial pressure of recumbent subjects cause some 
obvious limitations. The results regarding the VLF component should be dealt with 
caution, as durations of time series were inadequate to fully refl ect this spectral band. 
Additionally, no information is available on the cardiovascular reactivity to various 
challenges present in real life. For example, it is possible that short-term recordings in 
recumbent subjects lead to an underestimation of the relations between psychological 
factors and HRV. Although a respiratory rate of 15 per minute (0.25 Hz), used in 
studies II–V, may increase the HF component, controlled breathing importantly 
reduces the confounding effects of different breathing patterns on the results (22, 23). 
Because different methods were used for the evaluation of autonomic nervous function 
in the two study populations in study III, comparisons between the populations were 
avoided and attention was focused on the congruent observations from these carefully 
controlled materials.
There are some concerns regarding the generalization of the results. Firstly, a 
substantial number of subjects were excluded because of measurement inadequacy. 
However, this concern was tested in study I which showed that the resultant study 
groups were representative samples of the initial cohorts of subjects applicable to 
the study. Secondly, these fi ndings may be limited to subjects in an age group of 
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35–54 years (I) or 35–64 years (II–V). This concern may be justifi ed, because there 
is some evidence that the association between psychological factors and autonomic 
cardiovascular regulation is dependent on age (171). Finally, strict criteria were 
used to exclude subjects with any confounding medications or illnesses. Therefore 
the resultant samples, originated from population-based cohorts of subjects, 
represent exceptionally healthy individuals. This may moderate the results regarding 
associations between autonomic cardiovascular function and its determinants. For 
example, the exclusion of subjects using selective serotonin reuptake inhibitors might 
have affected the variation in depression scores among the study subjects contributing 
to the negative fi ndings. 
Because this study was cross-sectional, the data do not allow temporal analyses or 
conclusions regarding cause-effect relations. No defi nite conclusions can be drawn 
from the mechanisms accounting for the observations. A major limitation is that no 
direct measurements of arterial compliance or arterial stiffness were used. Further 
studies are indicated to corroborate the present fi ndings on a linkage between arterial 
stiffening and autonomic cardiovascular regulation, particularly with respect to BRS 
and beat-to-beat PP variability.
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7 CONCLUSIONS
1. Absolute measures of HRV (power spectral components, RMSSD and SDNN) 
are reduced in untreated middle-aged hypertensive subjects. Higher heart rate, 
advanced age, higher blood pressure, female gender, and higher plasma renin 
activity were independent determinants of decreased HRV when hypertensive 
patients and healthy controls were combined.
2 Psychological factors, particularly increased hostility and anxiety, are related to 
reduced BRS and to increased LF oscillations of APV in a healthy middle-aged 
general population.
3 Increased ambulatory PP is associated with reduced BRS and increased SAP 
variability in a healthy middle-aged general population.
4 Beat-to-beat variability of PP is composed of similar frequency peaks observed 
in the spectral analyses of R-R interval, SAP, and DAP variabilities, but has 
relatively larger HF component than those of SAP and DAP variabilities.
5 An increased beat-to-beat oscillation of PP is related to several risk factors of 
arterial stiffening, including age, PP, BMI, serum insulin concentration, insulin 
resistance, and serum triglyceride concentration. It is also related to impaired 
BRS in a healthy middle-aged general population. These associations suggest 
that increased beat-to-beat oscillation of PP may be determined by arterial 
stiffening and impaired barorefl ex function.
6 Factors related to the metabolic syndrome, e.g. hypertension, increased body 
fat percentage, insulin resistance, and high levels of serum triglycerides, are 
associated with decreased HRV and BRS and with increased HF power of APV 
in a healthy middle-aged population. A higher exercise capacity has opposite 
effects on the same parameters.
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